Skip to main content
Journal of Analytical Methods in Chemistry logoLink to Journal of Analytical Methods in Chemistry
. 2022 Feb 4;2022:2447945. doi: 10.1155/2022/2447945

Tissue Distribution of Total Flavonoids Extracts of Drynariae Rhizoma in Young and Old Rats by UPLC–MS/MS Determination

Yue Zhang 1, Xia Lei 2, Hongdan Xu 2, Guoliang Liu 2, Yeqiu Wang 2, Huifeng Sun 1, Fang Geng 3,, Ning Zhang 1,2,4,
PMCID: PMC8837432  PMID: 35154845

Abstract

Drynariae Rhizoma (Kunze ex Mett.) J. Sm. has been extensively used in China, Japan, and Korea to treat osteoporosis and tonify kidneys. A rapid and validated UPLC-MS/MS method for simultaneous determination of the seven analytes including neoeriocitrin, luteolin-7-O-β-D-glucoside, astragalin, naringin, eriodictyol, naringenin, and kaempferol in rats' various tissues (heart, liver, spleen, lung, kidney, stomach, brain, uterus, ovary, and small intestine) using quercetin as the internal standard (IS) was developed after oral administration of TFDR to rats. Tissues samples were retreated by protein precipitation with methanol. The chromatographic separation was performed using an ACQUITY UPLC™ BEH C18 column (2.1 × 50 mm; 1.7 μm) at 35°C. The mobile phase consisted of 1% acetic acid in water as the aqueous phase (A) and 100% acetonitrile as the organic phase (B). All analytes and IS were quantified through electrospray ionization in positive ion multiple reaction monitoring (MRM) mode. MS transitions were m/z 597.5 ⟶ 289.2 for neoeriocitrin, m/z 449.1 ⟶ 287.1 for luteolin-7-O-β-D-glucoside, m/z 449.1 ⟶ 287.1 for astragalin, m/z 581.5 ⟶ 273.2 for naringin, m/z 289.2 ⟶ 153.1 for eriodictyol, m/z 273.2 ⟶ 153.1 for naringenin, m/z 287.1 ⟶ 153.1 for kaempferol, and m/z 303.2 ⟶ 153.1 for quercetin (IS). The mean extraction recovery of the seven analytes and IS in tissue samples at three levels of quality control (QC) samples ranged from 82.72% to 118.57%, and the RSD was ≤14.98%. The intraday and interday precision (RSD) were all less than 14.98%, and the accuracy (RE) ranged from −13.96% to 14.96%, which indicated that the present method was not an issue. Tissues distribution showed neoeriocitrin, luteolin-7-O-β-D-glucoside, astragalin, naringin, and naringenin could transfer across the blood-brain barrier, which may form the basis of TFDR entering the brain to play an anti-AD role. Compared with the 8-month-old rats, a higher concentration of naringin was found in the ovaries of the 18-month-old rats; this result indicated that it may regulate the autonomic nervous dysfunction of the cerebrospinal system through the hypothalamus-pituitary-ovary axis, thus playing an anti-AD role, but further research is needed. Naringenin, eriodictyol, and kaempferol have a higher concentration in the liver and kidney; this phenomenon may be related to the traditional Chinese medicine theory that there is a definite relationship between the liver and kidney meridian. These results provide reliable data support for further study of the pharmacological mechanism of TFDR, formulation of drug delivery schemes, and development of new Chinese medicines in the treatment of AD.

1. Introduction

Alzheimer's disease (AD) is a kind of disease that leads to the decline of human memory and affects the cognitive function of the brain, which seriously threatens human life and health [1, 2]. According to traditional medicine, the main system of Alzheimer's disease is the deficiency of kidney qi, leading to insufficient marrow sea; thus, the brain tissue atrophy and functional decline. Therefore, herbal medicine possessing the efficacy of nourishing kidney essence or replenishing brain marrow are commonly served as effective strategies for AD treatment [37]. Drynariae Rhizoma is a common plant widely distributed in southern China [8]. Total Drynariae Rhizoma flavonoids is a classic Chinese herbal medicine that contains mainly flavonoids and is prepared based on the China Pharmacopoeia standard of quality control [9]. Total Drynariae Rhizoma flavonoids have been used in the clinic to nourish the kidneys, strengthen the bones, cure injuries, and relieve pains [10]. Studies have revealed that total flavonoids from Drynariae Rhizoma (TFDR) could promote fracture healing, and the mechanism is mainly delineated by improving blood circulation, relieving blood flow abnormalities, and preventing blood clots [11]. Drynariae Rhizoma is a classic Chinese medicine for invigorating the kidney and strengthening the bones, which is consistent with the treatment of Alzheimer's disease from the perspective of the basic theory of traditional Chinese medicine, and modern pharmacology shows that Drynaria fortunei has the function of improving learning and memory, and its main component is flavonoids [12, 13]. TFDR can activate estrogen receptors and has the tendency to replace estrogens in clinical practice [14]. In our previous study, using 55% ethanol reflux extraction and AB-8 macroporous resin as carrier, the total flavonoids content of Rhizoma Drynariae was 76.11%, in which naringin content was 20.41%. In the study of the protective effect of TFDR on PC12 cells induced by Aβ25-35, TFDR can effectively inhibit the death of PC12 cells induced by Aβ25-35 [15]. In the analysis of blood components and pharmacokinetics of SD rats fed with Gufangbu flavonoids by gavage, neoeriocitrin, luteolin-7-O-β-D-glucoside, astragalin, naringin, eriodictyol, luteolin, naringenin, and kaempferol (Figure 1) are thought as the active components of TFDR [16]. As we all know, pharmacokinetics studies could help greatly understand and confirm the efficacy and action mechanism of drugs as well as optimize benefit and reduce harm. There are many ingredients in TCM; not just a single component plays a role in TCM completely, but the outcome of many components combing action does. Until now, few studies have concentrated on tissues distribution study of these bioactive compounds in Drynariae Rhizoma.

Figure 1.

Figure 1

Chemical structures of seven analytes and IS.

In this study, a rapid and validated UPLC-MS/MS method for simultaneous determination of neoeriocitrin, luteolin-7-O-β-D-glucoside, astragalin, naringin, eriodictyol, naringenin, and kaempferol in rat tissue was successfully applied after oral administration of TFDR to rats. The study would also promote to safely and reasonably use Drynariae Rhizoma in the clinic.

2. Experimental Section

2.1. Chemicals, Reagents, and Analytical Conditions

The research content of this experiment is an in-depth study of the article “Pharmacokinetics of Eight Flavonoids in Rats Assayed by UPLC-MS/MS after Oral Administration of Drynariae rhizoma Extract” published in 2018. The preparation, quality evaluation, and analysis conditions of chemicals, reagents, and extracts are based on the experimental methods established in the early stage of the laboratory. See reference [16] for details.

2.2. Preparation of Calibration Standards and Quality Control Samples

Each reference compound was accurately weighed and dissolved in methanol/water (50/50, v/v) as a primary stock solution at the concentration of 1 mg/mL and was prepared as a series of standard or QC solutions at the desired concentrations by serial dilution. The IS working solution of 200 ng/mL was prepared by dilution of the stock standard solution with methanol/water (50/50, v/v). Different tissues calibration standard solutions were prepared at different concentrations for eight different flavonoids. Three concentrations (low, middle, and high concentrations) of each analyte solution in drug-free tissue were used for quality control (QC) evaluation in UPLC-MS/MS analysis. All the solutions were stored at 4°C and brought to room temperature before use.

2.3. Pretreatment of Tissue Samples

For tissue homogenate sample preparation, each weighed 0.2 g tissue sample was thawed, cut up into a 2 ml tube, and then homogenized in ice-cold physiological saline (5 ml/g tissue). Then 500 μl of tissue homogenate sample was mixed with 2 ml methanol containing 50 μl of internal standard solution (200 ng/ml) and 50 μl acetic acid in a 10 ml centrifuge tube. The mixture was then vortex-mixed for 2 min for the purpose of protein precipitation. After centrifuging at 14,000 ×g for 10 min, the supernatant was transferred into another centrifuge tube. The vortexing and centrifugation process was then repeated, and the two supernatants were combined and evaporated to dryness under a flow of nitrogen gas at 40°C. The residue was then dissolved in 100 μL methanol and vortexed for 1 min. Finally, the vortexing and centrifugation process was again repeated, and 5 μL of the supernatant was injected into the UPLC-MS/MS system for analysis.

2.4. Assay Validation

2.4.1. Selectivity

The selectivity of the method was determined by analyzing the MRM chromatograms of six different blank tissues homogenate samples, blank tissue homogenate spiked with seven analytes, and IS and tissue homogenate after administration of TFDR.

2.4.2. Calibration Curves and Lower Limit of Quantitation (LOQ)

Calibration curves of analytes were prepared by adding a series of different concentration working solutions and IS working solutions to tissues homogenate to determine the linearity and LOQ and assessed by weighted least-squares linear regression using 1/x2 as a weighting factor.

2.4.3. Precision and Accuracy

Intraday and interday precision and accuracy were determined by analyzing six replicates at three different QC samples (low, middle, and high concentrations).

2.4.4. Extraction Recovery and Matrix Effect

The extraction recovery was determined by comparing the peak areas between tissues homogenate samples spiked with analytes before and after extraction for low, middle, and high concentration QC samples with six replicates. The matrix effect was evaluated by comparing the peak areas between the low, middle, and high concentration QC samples spiked in blank tissue homogenate and pure standard solutions at the same concentrations with six replicates.

2.4.5. Stability

The stability of analytes was tested under different storage and process conditions for low, middle, and high concentrations QC samples with six replicates: store auto-sampler (4°C) for 36 h, keep in −20°C for 30 days, and perform three complete freeze/thaw cycles from −20°C to room temperature.

2.5. Tissue Distribution Study

2.5.1. Animals

Fifty-four 8-month-old and 18-month-old female Sprague-Dawley rats (280–350 g) were supplied by the Animal Safety Evaluation Center of Heilongjiang University of Chinese Medicine (Harbin, China). The rats were housed in an air-conditioned room at a temperature of 22 ± 2°C and relative humidity of 50 ± 10% with 12 h dark-light cycles and allowed food and water spontaneously. All protocols of animal experiments were approved in accordance with the regulations of Experimental Animal Administration issued by the Animal Ethics Committee of the institution.

2.5.2. Drug Administration and Sampling

Fifty-five 8-month-old and 18-month-old rats were randomly divided into 6 groups (9 rats per group), respectively. Before oral administration, rats were fasted overnight but allowed access to water freely. After oral administration of TFDR at a dose of 4 g/kg to each rat, tissues (heart, liver, spleen, lung, kidney, stomach, brain, uterus, ovary, and small intestine) were collected at 0, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 h. Tissue samples were rinsed with physiological saline to remove the blood, then blotted on filter paper, and stored at −80°C until analysis.

3. Results and Discussion

3.1. LC-MS Conditions

The molecular weight, parent ion, daughter ion, cone voltage, collision energy, and retention time of the seven flavonoids and IS are shown in Table 1.

Table 1.

Precursor ion and product ion transition and parameters of the analytes used in this study.

Analytes Retention time (min) Precursor ion species MRM transition Cone (V) Collision (V) Dwell time (ms)
Precursor ion Product ion
Neoeriocitrin 2.20 [M+H]+ 597.5 289.2 25 30 0.2
Luteolin-7-O-β-D-glucoside 2.36 [M+H]+ 449.1 287.1 20 20 0.2
Astragalin 2.60 [M+H]+ 449.1 287.1 30 30 0.2
Naringin 2.69 [M+H]+ 581.5 273.2 20 25 0.2
Eriodictyol 3.31 [M+H]+ 289.2 153.1 30 25 0.2
Naringenin 4.34 [M+H]+ 273.2 153.1 20 30 0.2
Kaempferol 4.43 [M+H]+ 287.1 153.1 30 30 0.2
Quercetin (IS) 3.42 [M+H]+ 303.2 153.1 20 25 0.2

3.2. Assay Validation

3.2.1. Selectivity

The chromatograms of blank tissues homogenate sample, blank tissues homogenate sample spiked with seven analytes and IS, and tissue homogenate after administration of TFDR are shown in Figure 2. No interfering from endogenous components was observed in the retention time of the seven analytes and IS, which demonstrated an acceptable selectivity in the conditions.

Figure 2.

Figure 2

Representative MRM chromatograms of seven analytes and quercetin (IS): (a) blank liver homogenates; (b) blank liver homogenates spiked with the seven analytes and IS; and (c) liver homogenates 1 h after oral administration of TFDR (4 g/kg; mean ± SD; n = 6).

3.2.2. Calibration Curves and Lower Limit of Quantitation (LOQ)

The regression equation, correlation coefficient, and linear ranges of the seven analytes in various tissues are listed in Table 2. In the detection of tissue homogenate samples, correlation coefficients (R2) of calibration curves were greater than 0.999, showed good linearity over the concentration ranges for the seven analytes. The LOQ in various tissues is presented in Table 2. The present LOQ with a signal-to-noise ratio >10 was sensitive enough to investigate seven analytes after oral administration of TFDR.

Table 2.

The linear equations and range of seven analytes in different rats' tissues.

Analytes Tissue Regression equation Correlation coefficient Concentration range (ng/mL) Standard error (slope) Standard error (intercept)
Neoeriocitrin Heart y = 0.9013x + 5.1928 R 2 = 0.9991 5–500 4.0987 0.0146
Liver y = 0.0972x + 36.321 R 2 = 0.9991 10–5,000 3.8552 0.0014
Spleen y = 0.0931x + 11.703 R 2 = 0.9997 5–10,000 4.6785 0.0008
Lung y = 0.1685x + 12.194 R 2 = 0.9990 10–10,000 5.9655 0.4775
Kidney y = 1.195x + 5.4235 R 2 = 0.9997 5–500 4.0379 0.0144
Brain y = 2.7542x − 1.5057 R 2 = 0.9991 5–100 2.5959 0.0464
Stomach y = 0.1753x + 20.86 R 2 = 0.9992 5–10,000 10.5855 0.0023
Uterus y = 1.5008x − 4.2356 R 2 = 0.9991 5–500 7.4003 0.0265
Ovary y = 1.8168x − 7.1718 R 2 = 0.9994 5–500 7.3924 0.0264
Intestine y = 0.0948x + 22.078 R 2 = 0.9992 5–10,000 5.9586 0.0013
Luteolin-7-O-β-D-glucoside Heart y = 17.011x − 11.593 R 2 = 0.9996 2–50 5.3807 0.1925
Liver y = 14.803x − 5.3733 R 2 = 0.9996 2–50 4.6633 0.1668
Spleen y = 19.649x − 27.686 R 2 = 0.9992 2–50 8.9679 0.3209
Lung y = 27.742x + 144.06 R 2 = 0.9990 5–100 18.3343 0.5063
Kidney y = 22.7x − 30.98 R 2 = 0.9992 2–50 10.4027 0.3722
Brain y = 17.311x − 0.2042 R 2 = 0.9995 2–50 6.0981 0.2182
Stomach y = 25.13x − 45.82 R 2 = 0.9997 5–100 14.4218 0.2579
Uterus y = 22.459x − 27.379 R 2 = 0.9993 2–50 9.7807 0.3500
Ovary y = 15.526x − 28.948 R 2 = 0.9995 2–50 5.2243 0.1869
Intestine y = 23.444x − 62.646 R 2 = 0.9990 5–100 3.2885 0.4166

Astragalin Heart y = 33.567x − 145.2 R 2 = 0.9998 5–100 14.7494 0.2638
Liver y = 28.213x − 115.87 R 2 = 0.9991 5–100 27.4261 0.4906
Spleen y = 38.234x − 66.065 R 2 = 0.9998 2–50 8.4768 0.3033
Lung y = 52.063x − 119.94 R 2 = 0.9991 5–100 10.7568 0.2546
Kidney y = 18.133x − 32.32 R 2 = 0.9993 2–50 7.7062 0.2757
Brain y = 5.7194x + 13.483 R 2 = 0.9994 2–50 2.3118 0.0827
Stomach y = 52.209x − 32.98 R 2 = 0.9991 5–250 9.2349 0.9419
Uterus y = 43.952x − 104.76 R 2 = 0.9993 5–50 8.5206 0.6613
Ovary y = 33.871x − 78.24 R 2 = 0.9993 5–100 5.5678 0.5468
Intestine y = 41.795x − 203.61 R 2 = 0.9991 5–100 4.2632 0.0762

Naringin Heart y = 8.8875x − 16.6369 R 2 = 0.9990 5–1,000 3.0936 0.0878
Liver y = 2.2546x − 2.937 R 2 = 0.9996 10–10,000 7.5588 0.0015
Spleen y = 2.3615x + 62.727 R 2 = 0.9992 5–10,000 7.5326 0.0057
Lung y = 2.7462x + 20.433 R 2 = 0.9997 5–10,000 1.0489 0.0839
Kidney y = 1.4648x + 125.32 R 2 = 0.9993 5–10,000 10.7813 0.0128
Brain y = 5.1578x +9.1048 R 2 = 0.9990 5–1,000 4.0361 0.0388
Stomach y = 2.4286x + 376.32 R 2 = 0.9993 5–20,000 14.1719 0.0236
Uterus y = 3.9995x + 43.448 R 2 = 0.9990 5–5,000 9.2749 0.0171
Ovary y = 1.6439x + 171.55 R 2 = 0.9995 5–10,000 8.4004 0.0075
Intestine y = 2.4255x + 344.31 R 2 = 0.9990 5–20,000 4.4006 0.0207

Eriodictyol Liver y = 25.147x − 94.45 R 2 = 0.9994 5–100 6.1292 0.1096
Spleen y = 9.1535x − 8.4711 R 2 = 0.9995 2–50 1.4348 0.0513
Lung y = 16.877x − 61.056 R 2 = 0.9992 5–100 7.2109 0.1289
Stomach y = 26.831x − 85.59 R 2 = 0.9991 5–250 10.1807 0.1236
Uterus y = 11.401x − 3.982 R 2 = 0.9995 2–50 5.3807 0.1925
Ovary y = 18.425x − 65.716 R 2 = 0.9992 5–100 4.4218 0.2579
Intestine y = 25.138x − 3.45 R 2 = 0.9993 5–250 4.3516 0.3611

Naringenin Heart y = 21.6837x + 27.6507 R 2 = 0.9996 5–250 9.4029 0.1579
Liver y = 27.289x + 323.82 R 2 = 0.9995 5–1,000 6.6046 0.2573
Spleen y = 25.421x − 23.549 R 2 = 0.9991 5–250 6.4353 0.3780
Lung y = 36.466x − 98.509 R 2 = 0.9992 5–250 3.8363 0.1696
Kidney y = 20.267x + 108.13 R 2 = 0.9990 5–250 8.1007 0.3102
Brain y = 5.1578x +9.1048 R 2 = 0.9990 2–50 2.5110 0.0898
Stomach y = 23.599x + 267.38 R 2 = 0.9996 5–1,000 6.5617 0.2572
Uterus y = 27.424x − 20.783 R 2 = 0.9990 5–250 1.1989 0.0976
Ovary y = 29.424x − 112.58 R 2 = 0.9995 5–250 1.1010 0.0822
Intestine y = 30.804x − 2.1048 R 2 = 0.9991 5–1,000 1.3461 0.2736

Kaempferol Liver y = 13.699x − 62.076 R 2 = 0.9992 5–100 9.1285 0.2192
Spleen y = 10.466x − 41.289 R 2 = 0.9997 10–250 2.5830 0.1024
Lung y = 7.384x + 18.317 R 2 = 0.9997 2–50 2.0984 0.0751
Kidney y = 3.2041x − 2.1837 R 2 = 0.9991 10–100 3.3257 0.0593
Stomach y = 12.132x + 31.51 R 2 = 0.9995 2–50 4.3045 0.1540
Uterus y = 11.729x − 9.8825 R 2 = 0.9990 2–50 5.8182 0.2082
Intestine y = 19.205x − 17.2 R 2 = 0.9992 5–500 5.4486 0.2215

3.2.3. Precision and Accuracy

The intraday and interday precision and accuracy of the seven analytes in the various tissues at three different QC levels (low, middle, and high) were estimated and are shown in Tables 39. The intraday and interday precision (RSD) were all less than 14.98%, and the accuracy (RE) ranged from −13.96% to 14.96%, which indicated that the present method was not a problem.

Table 3.

Interday and intraday precision and accuracy data for assays of neoeriocitrin in different tissues (n = 6).

Tissues Spiked (ng/mL) Interday Intraday
Mean ± SD Precision (RSD, %) Relative error (RE, %) Mean ± SD Precision (RSD, %) Relative error (RE, %)
Heart 8.10 7.54 ± 1.12 14.85 −6.91 7.96 ± 1.17 14.70 −1.73
121.50 112.95 ± 15.71 13.91 −7.04 113.71 ± 16.05 14.11 −6.41
243.00 261.48 ± 27.13 10.38 7.60 262.09 ± 29.96 11.43 7.86

Liver 12.20 10.49 ± 1.06 10.10 −14.02 10.47 ± 1.27 12.13 −14.18
610.00 594.67 ± 14.10 2.37 −2.51 590.92 ± 16.50 2.79 −3.13
3,660.00 3,358.79 ± 264.49 7.87 −8.23 3,397.03 ± 245.48 7.23 −7.18

Spleen 8.10 9.28 ± 0.54 5.82 14.57 9.17 ± 0.57 6.22 13.21
810.00 803.86 ± 14.51 1.81 −0.76 811.04 ± 12.00 1.48 0.13
4,050.00 3,809.56 ± 481.25 12.63 −5.94 3,797.20 ± 425.73 11.21 6.24

Lung 12.20 12.59 ± 1.15 9.13 3.20 12.35 ± 1.27 10.28 1.23
1,220.00 1,056.82 ± 116.83 11.05 −13.38 1,094.38 ± 129.81 11.86 −10.30
4,880.00 4,674.43 ± 120.35 2.57 −4.21 4,678.96 ± 145.06 3.10 −4.12

Kidney 8.10 9.27 ± 0.29 3.13 14.44 9.04 ± 0.23 2.54 11.60
121.50 122.73 ± 17.94 14.62 1.01 118.66 ± 16.84 14.19 −2.34
243.00 240.32 ± 35.32 14.70 −1.10 249.55 ± 37.09 14.86 2.70

Brain 8.10 8.80 ± 1.31 14.89 8.64 9.21 ± 0.89 9.66 13.70
40.50 35.93 ± 5.23 14.56 −11.28 37.35 ± 5.10 13.65 −7.78
81.00 87.50 ± 6.45 7.37 8.02 86.92 ± 7.89 9.08 7.31

Stomach 8.10 9.15 ± 0.89 9.73 12.96 8.38 ± 0.77 9.19 3.46
810.00 888.08 ± 50.38 5.67 9.64 902.84 ± 41.59 4.61 11.46
4,050.00 4,190.72 ± 365.94 8.73 3.47 4,373.61 ± 275.62 6.30 7.99

Uterus 8.10 8.86 ± 1.27 14.33 9.38 9.11 ± 1.36 14.93 12.47
121.50 119.15 ± 15.40 12.92 −1.93 121.49 ± 13.61 11.20 −0.01
243.00 233.53 ± 32.20 13.79 −3.90 237.59 ± 25.69 10.81 −2.23

Ovary 8.10 7.95 ± 1.03 12.96 −1.85 8.01 ± 1.02 12.73 −1.11
121.50 109.23 ± 11.97 10.96 −10.10 115.29 ± 9.59 8.32 −5.11
243.00 231.95 ± 30.92 13.33 −4.55 232.67 ± 30.02 12.90 −4.25

Intestine 8.10 8.76 ± 0.81 9.25 8.15 8.96 ± 0.74 8.26 10.62
810.00 783.47 ± 54.18 6.92 −3.28 763.63 ± 29.14 3.82 -5.72
4,050.00 4,236.54 ± 411.35 9.71 4.61 4,218.46 ± 458.40 10.87 4.16
Table 4.

Interday and intraday precision and accuracy data for assays of luteolin-7-O-β-D-glucoside in different tissues (n = 6).

Tissues Spiked (ng/mL) Interday Intraday
Mean ± SD Precision (RSD, %) Relative error (RE, %) Mean ± SD Precision (RSD, %) Relative error (RE, %)
Heart 5.05 5.09 ± 0.56 11.00 0.79 5.22 ± 0.64 12.26 3.37
10.10 9.74 ± 1.30 13.35 −3.56 10.28 ± 1.15 11.19 1.78
25.25 23.44 ± 2.76 11.77 −7.17 22.49 ± 2.68 11.92 −10.93

Liver 5.05 4.81 ± 0.69 14.35 −4.75 4.95 ± 0.70 14.14 −1.98
10.10 9.23 ± 0.98 10.62 −8.61 9.12 ± 1.17 12.83 −9.70
25.25 24.52 ± 2.55 10.40 −2.89 25.12 ± 1.67 6.65 −0.51

Spleen 5.05 4.70 ± 0.62 13.19 −6.93 4.86 ± 0.70 14.40 −3.76
10.10 10.67 ± 1.51 14.15 5.64 11.05 ± 1.45 13.12 9.41
25.25 25.98 ± 1.62 6.24 2.89 25.97 ± 1.08 4.16 2.85

Lung 8.10 8.61 ± 0.64 7.43 6.30 8.87 ± 0.64 7.22 9.51
40.50 39.29 ± 5.51 14.02 −2.99 36.05 ± 2.02 5.60 −10.99
81.00 82.44 ± 3.24 3.93 1.78 82.32 ± 3.53 4.29 1.63

Kidney 5.05 4.90 ± 0.62 12.65 −2.97 4.78 ± 0.56 11.72 −5.35
10.10 10.43 ± 1.50 14.38 3.27 10.70 ± 1.45 13.55 5.94
25.25 25.07 ± 2.34 9.33 −0.71 24.93 ± 2.90 11.63 −1.27

Brain 5.05 4.82 ± 0.43 8.92 −4.55 4.63 ± 0.41 8.86 −8.32
10.10 10.40 ± 1.48 14.23 2.97 10.36 ± 1.09 10.52 2.57
25.25 24.69 ± 3.04 12.31 −2.22 25.89 ± 3.01 11.63 2.53

Stomach 8.10 7.94 ± 0.76 9.57 −1.98 7.55 ± 0.28 3.71 −6.79
40.50 40.41 ± 4.15 10.27 −0.22 39.04 ± 2.31 5.92 −3.60
81.00 81.58 ± 5.19 6.36 0.72 83.26 ± 5.63 6.76 2.79

Uterus 5.05 4.60 ± 0.61 13.26 −8.91 4.57 ± 0.54 11.82 −9.50
10.10 8.99 ± 0.43 4.78 −10.99 9.08 ± 0.52 5.73 −10.10
25.25 24.19 ± 2.98 12.32 −4.20 23.33 ± 2.55 10.93 −7.60

Ovary 5.05 4.57 ± 0.63 13.79 −9.50 4.74 ± 0.71 14.98 −6.14
10.10 9.61 ± 1.37 14.26 −4.85 9.90 ± 1.37 13.84 −1.98
25.25 24.48 ± 1.22 4.98 −3.05 23.78 ± 0.63 2.65 −5.82

Intestine 8.10 8.19 ± 1.02 12.45 1.11 7.63 ± 0.65 8.52 −5.80
40.50 39.08 ± 5.23 13.38 −3.51 37.96 ± 3.89 10.25 −6.27
81.00 82.05 ± 9.79 11.93 1.30 78.50 ± 10.40 13.25 −3.09
Table 5.

Interday and intraday precision and accuracy data for assays of astragalin in different tissues (n = 6).

Tissues Spiked (ng/mL) Interday Intraday
Mean ± SD Precision (RSD, %) Relative error (RE, %) Mean ± SD Precision (RSD, %) Relative error (RE, %)
Heart 8.10 8.08 ± 1.07 13.24 −0.25 7.91 ± 0.93 11.76 −2.35
40.50 38.56 ± 3.40 8.82 −4.79 37.90 ± 3.94 10.40 −6.42
81.00 84.75 ± 8.92 10.53 4.63 83.60 ± 11.21 13.41 3.21

Liver 8.10 9.12 ± 1.20 13.16 12.59 9.08 ± 1.06 11.67 12.10
40.50 37.17 ± 4.65 12.51 −8.22 36.06 ± 3.97 11.01 −10.96
81.00 82.91 ± 5.22 6.30 2.36 82.43 ± 3.95 4.79 1.77

Spleen 5.05 4.55 ± 0.60 13.19 −9.90 4.61 ± 0.52 11.28 −8.71
10.10 11.51 ± 1.47 12.77 13.96 11.42 ± 1.23 10.77 13.07
25.25 24.75 ± 3.68 14.87 −1.98 22.94 ± 3.07 13.38 −9.15

Lung 8.10 8.78 ± 1.09 12.41 8.40 8.85 ± 1.24 14.01 9.26
40.50 43.12 ± 4.18 9.69 6.47 42.70 ± 2.98 6.98 5.43
81.00 85.32 ± 6.58 7.71 5.33 86.32 ± 5.75 6.66 6.57

Kidney 5.05 4.66 ± 0.64 13.73 −7.72 4.98 ± 0.51 10.24 −1.39
10.10 10.23 ± 1.26 12.32 1.29 10.39 ± 1.23 11.84 2.87
25.25 23.85 ± 3.52 14.76 −5.54 23.85 ± 3.21 13.46 −5.54

Brain 5.05 4.95 ± 0.72 14.55 −1.98 4.65 ± 0.61 13.12 −7.92
10.10 9.43 ± 1.15 12.20 −6.63 8.89 ± 0.87 9.79 −11.98
25.25 23.40 ± 2.89 12.35 −7.33 22.85 ± 2.34 10.24 −9.50

Stomach 8.10 8.89 ± 1.20 13.50 9.75 9.13 ± 1.32 14.46 12.72
81.00 86.11 ± 8.14 9.45 6.31 87.58 ± 9.09 10.38 8.12
162.00 154.67 ± 21.08 13.63 −4.52 165.48 ± 16.47 9.95 2.15

Uterus 5.05 4.80 ± 0.60 12.50 −4.95 4.61 ± 0.46 9.98 −8.71
10.10 10.15 ± 1.47 14.48 0.50 9.68 ± 1.30 13.43 −4.16
25.25 25.85 ± 3.22 12.46 2.38 25.33 ± 3.72 14.69 0.32

Ovary 8.10 9.10 ± 1.21 13.30 12.35 9.11 ± 1.22 13.39 12.47
40.50 41.81 ± 6.20 14.83 3.23 44.33 ± 5.85 13.20 9.46
81.00 87.39 ± 12.01 13.74 7.89 85.47 ± 11.40 13.34 5.52

Intestine 8.10 9.13 ± 1.27 13.91 12.72 8.71 ± 1.12 12.86 7.53
40.50 38.26 ± 5.07 13.25 −5.53 40.21 ± 5.18 12.88 −0.72
81.00 82.56 ± 8.73 10.57 1.93 78.73 ± 8.08 10.26 −2.80
Table 6.

Interday and intraday precision and accuracy data for assays of naringin in different tissues (n = 6).

Tissues Spiked (ng/mL) Interday Intraday
Mean ± SD Precision (RSD, %) Relative error (RE, %) Mean ± SD Precision (RSD, %) Relative error (RE, %)
Heart 8.10 9.24 ± 1.38 14.94 14.07 9.16 ± 1.26 13.76 13.09
405.00 380.94 ± 43.17 11.33 −5.94 377.25 ± 55.15 14.62 −6.85
810.00 836.12 ± 75.60 9.04 3.22 837.23 ± 64.62 7.72 3.36

Liver 12.20 11.91 ± 1.16 9.74 −2.38 12.22 ± 1.31 10.72 0.16
1,220.00 1,083.38 ± 128.98 11.91 −11.20 1,118.43 ± 150.05 13.42 −8.33
4,880.00 4,989.75 ± 685.15 13.73 2.25 4,904.97 ± 645.18 13.15 0.51

Spleen 8.10 9.10 ± 1.26 13.85 12.35 8.83 ± 1.26 14.27 9.01
810.00 825.26 ± 66.35 8.04 1.88 854.30 ± 62.59 7.33 5.47
4,050.00 4,004.43 ± 587.31 14.67 −1.12 4,178.48 ± 568.58 13.61 3.17

Lung 8.10 9.21 ± 0.84 9.12 13.70 9.15 ± 0.83 9.07 12.96
810.00 845.41 ± 101.35 11.99 4.37 839.70 ± 119.76 14.26 3.67
4,050.00 4,011.38 ± 587.19 14.64 −0.95 4,247.34 ± 556.90 13.11 4.87

Kidney 8.10 8.98 ± 1.06 11.80 10.86 8.69 ± 0.54 6.21 7.28
810.00 863.67 ± 90.41 10.47 6.63 878.63 ± 109.04 12.41 8.47
4,050.00 3,956.27 ± 574.77 14.53 −2.31 4,029.43 ± 591.13 14.67 −0.51

Brain 8.10 8.13 ± 1.08 13.28 0.37 8.53 ± 1.14 13.36 5.31
405.00 415.00 ± 51.43 12.39 2.47 399.72 ± 52.49 13.13 −1.30
810.00 849.97 ± 118.72 13.97 4.93 889.89 ± 130.79 14.70 9.86

Stomach 8.10 8.92 ± 1.22 13.68 10.12 9.03 ± 1.07 11.85 11.48
810.00 783.57 ± 92.13 11.76 −3.26 754.08 ± 70.59 9.36 −6.90
8,100.00 7,802.03 ± 571.75 7.33 −3.68 7,806.89 ± 735.92 9.43 −3.62

Uterus 8.10 9.02 ± 0.89 9.87 11.36 9.22 ± 0.73 7.92 13.83
1,215.00 1,257.33 ± 168.44 13.40 3.48 1,233.89 ± 179.47 14.55 1.55
2,430.00 2,361.88 ± 303.00 12.83 −2.80 2,311.52 ± 291.80 12.62 −4.88

Ovary 8.10 8.63 ± 1.19 13.79 6.54 9.12 ± 1.06 11.62 12.59
810.00 857.76 ± 56.18 6.55 5.90 869.99 ± 58.59 6.73 7.41
4,050.00 4,025.32 ± 476.37 11.83 −0.61 4,004.08 ± 498.00 12.44 −1.13

Intestine 8.10 8.74 ± 1.28 14.65 7.90 8.73 ± 1.21 13.86 7.78
810.00 848.01 ± 108.63 12.81 4.69 818.73 ± 113.46 13.86 1.08
8,100.00 8,290.57 ± 1,207.41 14.56 2.35 8,888.41 ± 968.47 10.90 9.73
Table 7.

Interday and intraday precision and accuracy data for assays of eriodictyol in different tissues (n = 6).

Tissues Spiked (ng/mL) Interday Intraday
Mean ± SD Precision (RSD, %) Relative error (RE, %) Mean ± SD Precision (RSD, %) Relative error (RE, %)
Liver 8.10 8.90 ± 1.28 14.38 9.88 8.58 ± 1.25 14.57 5.93
40.50 38.20 ± 4.04 10.58 −5.68 36.81 ± 3.60 9.78 −9.11
81.00 84.30 ± 10.68 12.67 4.07 86.45 ± 11.11 12.85 6.73

Spleen 5.05 4.90 ± 0.55 11.22 −2.97 4.75 ± 0.65 13.68 −5.94
10.10 11.50 ± 0.98 8.52 13.86 11.61 ± 1.12 9.65 14.95
25.25 22.66 ± 2.81 12.40 −10.26 22.78 ± 2.62 11.50 −9.78

Lung 8.10 8.59 ± 0.90 10.48 6.05 9.11 ± 0.49 5.38 12.47
40.50 41.34 ± 5.82 14.08 2.07 43.80 ± 5.67 12.95 8.15
81.00 81.34 ± 10.47 12.87 0.42 78.13 ± 9.28 11.88 −3.54

Stomach 8.10 9.14 ± 1.31 14.33 12.84 9.21 ± 1.18 12.81 13.70
81.00 81.91 ± 7.07 8.63 1.12 80.93 ± 7.10 8.77 −0.09
162.00 159.83 ± 23.14 14.48 −1.34 166.06 ± 24.72 14.89 2.51

Uterus 5.05 5.24 ± 0.74 14.12 3.76 5.43 ± 0.63 11.60 7.52
10.10 10.16 ± 1.38 13.58 0.59 10.34 ± 1.39 13.44 2.38
25.25 22.68 ± 2.90 12.79 −10.18 22.85 ± 3.59 13.09 −9.50

Ovary 8.10 8.91 ± 1.06 11.90 10.00 8.55 ± 1.08 12.63 5.56
40.50 38.38 ± 5.30 13.81 −5.23 39.78 ± 4.77 11.99 −1.78
81.00 87.31 ± 7.86 9.00 7.79 91.95 ± 4.08 4.44 13.52

Intestine 8.10 8.83 ± 1.18 13.36 9.01 8.92 ± 1.01 11.32 10.12
81.00 80.17 ± 9.98 12.45 −1.02 80.27 ± 10.22 12.73 −0.90
162.00 175.52 ± 20.24 11.53 8.35 176.33 ± 21.61 12.26 8.85
Table 8.

Interday and intraday precision and accuracy data for assays of naringenin in different tissues (n = 6).

Tissues Spiked (ng/mL) Interday Intraday
Mean ± SD Precision (RSD, %) Relative error (RE, %) Mean ± SD Precision (RSD, %) Relative error (RE, %)
Heart 8.10 8.13 ± 1.13 13.90 0.37 8.16 ± 1.08 13.24 0.74
81.00 82.92 ± 8.68 10.47 2.37 86.88 ± 6.85 7.88 7.26
162.00 160.32 ± 22.94 14.31 −1.04 167.09 ± 24.86 14.88 3.14

Liver 8.10 8.63 ± 1.20 13.90 6.54 9.09 ± 1.24 13.64 12.22
405.00 427.60 ± 51.68 12.09 5.58 453.02 ± 42.58 9.40 11.86
810.00 775.22 ± 90.48 11.67 −4.29 817.22 ± 80.89 9.90 0.89

Spleen 8.10 9.24 ± 1.01 10.93 14.07 9.13 ± 0.93 10.19 12.72
81.00 85.43 ± 6.78 7.94 5.47 86.86 ± 4.52 5.20 7.23
162.00 152.55 ± 18.72 12.27 −5.83 151.26 ± 21.45 14.18 −6.63

Lung 8.10 8.81 ± 1.26 14.30 8.77 8.69 ± 0.54 6.21 7.28
81.00 79.67 ± 9.12 11.45 −1.64 83.38 ± 8.76 10.51 2.94
162.00 155.57 ± 22.84 14.68 −3.97 151.47 ± 19.85 13.10 −6.50

Kidney 8.10 8.43 ± 1.12 13.29 4.07 8.70 ± 1.21 13.91 7.41
81.00 82.07 ± 8.79 10.71 1.32 85.59 ± 7.93 9.27 5.67
162.00 163.46 ± 24.17 14.79 0.90 177.97 ± 10.54 5.92 9.86

Brain 5.05 4.71 ± 0.64 13.59 −6.73 4.76 ± 0.71 14.92 −5.74
10.10 11.12 ± 1.54 13.85 10.10 11.00 ± 1.54 14.00 8.91
25.25 26.41 ± 3.44 13.03 4.59 26.19 ± 3.45 13.17 3.72

Stomach 8.10 8.99 ± 1.19 13.24 10.99 8.91 ± 0.81 9.09 10.00
405.00 412.81 ± 58.73 14.23 1.93 441.06 ± 49.05 11.12 8.90
810.00 833.38 ± 105.06 12.61 2.89 818.43 ± 80.14 9.79 1.04

Uterus 8.10 8.57 ± 1.13 13.19 5.80 8.96 ± 1.06 11.83 10.62
81.00 79.55 ± 10.82 13.60 −1.79 80.82 ± 11.94 14.77 −0.22
162.00 163.07 ± 24.08 14.77 0.66 171.73 ± 24.88 14.49 6.01

Ovary 8.10 8.29 ± 1.08 13.03 2.35 8.66 ± 1.18 13.63 6.91
81.00 82.27 ± 10.04 12.20 1.57 84.42 ± 12.23 14.49 4.22
162.00 163.78 ± 23.19 14.16 1.10 164.51 ± 17.65 10.73 1.55

Intestine 8.10 7.63 ± 0.85 11.14 −5.80 7.78 ± 1.05 13.50 −3.95
405.00 404.43 ± 55.41 13.70 −0.14 428.48 ± 52.94 12.36 5.80
810.00 770.23 ± 82.03 10.65 −4.91 784.08 ± 102.02 13.01 −3.20
Table 9.

Interday and intraday precision and accuracy data for assays of kaempferol in different tissues (n = 6).

Tissues Spiked (ng/mL) Interday Intraday
Mean ± SD Precision (RSD, %) Relative error (RE, %) Mean ± SD Precision (RSD, %) Relative error (RE, %)
Liver 8.10 8.50 ± 1.23 14.47 4.94 8.36 ± 1.19 14.23 3.21
40.50 45.97 ± 6.78 14.75 13.51 45.61 ± 5.04 11.05 12.62
81.00 82.90 ± 11.10 13.39 2.35 85.23 ± 12.01 14.09 5.22

Spleen 12.20 11.06 ± 1.54 13.92 −9.34 10.75 ± 0.72 6.70 −11.89
91.50 97.07 ± 12.65 13.03 6.09 94.94 ± 10.93 11.51 3.76
183.00 188.84 ± 25.77 13.65 3.19 180.04 ± 22.90 12.72 −1.62

Lung 5.05 5.08 ± 0.63 12.40 0.59 4.76 ± 0.30 6.30 −5.74
10.10 9.34 ± 1.28 13.70 −7.52 8.67 ± 0.50 5.77 −14.16
25.25 23.74 ± 3.26 13.73 −5.98 22.77 ± 3.05 13.39 −9.82

Kidney 12.20 10.71 ± 1.12 10.46 −12.21 11.37 ± 0.55 4.84 −6.80
42.70 41.36 ± 4.67 11.29 −3.14 43.56 ± 4.11 9.44 2.01
85.40 86.37 ± 8.43 9.76 1.14 90.48 ± 6.45 7.13 5.95

Stomach 5.05 4.81 ± 0.69 14.35 −4.75 4.82 ± 0.59 12.24 −4.55
10.10 10.51 ± 1.41 13.42 4.06 10.64 ± 1.47 13.82 5.35
25.25 24.14 ± 3.37 13.96 −4.40 25.50 ± 3.41 13.37 0.99

Uterus 5.05 4.89 ± 0.54 11.04 −3.17 4.91 ± 0.50 10.18 −2.77
10.10 10.35 ± 1.41 13.62 2.48 10.16 ± 1.10 10.83 0.59
25.25 24.16 ± 2.84 11.75 −4.32 23.47 ± 3.31 14.10 −7.05

Intestine 8.10 8.31 ± 1.04 12.52 2.59 8.32 ± 1.15 13.82 2.72
121.50 105.10 ± 11.92 11.34 −13.50 104.54 ± 5.05 4.83 −13.96
243.00 264.29 ± 39.44 14.92 8.76 271.43 ± 36.43 13.42 11.70

3.2.4. Extraction Recovery and Matrix Effect

The mean extraction recovery of the seven analytes and IS in tissue samples at three levels of QC samples ranged from 82.72% to 118.57%, and the RSD was ≤14.98%. The matrix effect value was obtained for the seven analytes and IS ranged from 84.95% to 117.51% within 14.98% RSD. The results in Tables 1016 suggested that the extraction recovery and matrix effect for the seven analytes and IS were in the acceptable range, and there is no interference from endogenous components.

Table 10.

Recovery and matrix effect study of neoeriocitrin in rat tissues (n = 6).

Tissues Spiked (ng/mL) Recovery Matrix effects
Mean (%) ± SD RSD (%) Mean (%) ± SD RSD (%)
Heart 8.10 94.72 ± 14.10 14.89 95.70 ± 13.74 14.36
121.50 91.22 ± 13.65 14.96 95.21 ± 13.09 13.75
243.00 105.88 ± 11.56 10.92 109.53 ± 11.31 10.33

Liver 12.20 86.98 ± 9.39 10.80 84.95 ± 9.27 10.91
610.00 97.31 ± 2.54 2.61 97.17 ± 2.44 2.51
3,660.00 90.68 ± 7.51 8.28 93.69 ± 6.13 6.54

Spleen 8.10 115.23 ± 7.17 6.22 115.8 ± 6.58 5.68
810.00 99.6 ± 1.74 1.75 99.59 ± 1.76 1.77
4,050.00 91.21 ± 10.74 11.78 96.67 ± 11.20 11.59

Lung 12.20 103.66 ± 10.52 10.15 101.25 ± 9.04 8.93
1,220.00 87.54 ± 10.41 11.89 88.18 ± 9.83 11.15
4,880.00 95.55 ± 2.68 2.80 96.10 ± 2.62 2.73

Kidney 8.10 114.05 ± 3.81 3.34 115.65 ± 2.59 2.24
121.50 100.88 ± 14.50 14.37 98.47 ± 14.56 14.79
243.00 98.5 ± 14.22 14.44 102.34 ± 13.24 12.94

Brain 8.10 111.41 ± 14.50 13.01 112.94 ± 13.84 12.25
40.50 90.48 ± 13.11 14.49 89.76 ± 13.16 14.66
81.00 107.02 ± 8.46 7.91 108.47 ± 8.82 8.13

Stomach 8.10 112 ± 12.00 10.71 116.4 ± 8.33 7.16
810.00 109.15 ± 6.82 6.25 111.59 ± 4.46 4.00
4,050.00 105.59 ± 7.97 7.55 104.97 ± 8.96 8.54

Uterus 8.10 108.3 ± 14.27 13.18 113.04 ± 14.59 12.91
121.50 101.6 ± 10.34 10.18 96.07 ± 13.08 13.62
243.00 97.02 ± 14.20 14.64 96.53 ± 14.07 14.58

Ovary 8.10 98.12 ± 14.25 14.52 98.86 ± 14.13 14.29
121.50 91.95 ± 9.48 10.31 91.85 ± 9.65 10.51
243.00 92.92 ± 12.43 13.38 98.22 ± 12.04 12.26

Intestine 8.10 107.31 ± 10.98 10.23 111.09 ± 7.96 7.17
810.00 97.25 ± 7.34 7.55 94.24 ± 3.12 3.31
4,050.00 106.03 ± 10.66 10.05 102.82 ± 10.25 9.97
Table 11.

Recovery and matrix effect study of luteolin-7-O-β-D-glucoside in rat tissues (n = 6).

Tissues Spiked (ng/mL) Recovery Matrix effects
Mean (%) ± SD RSD (%) Mean (%) ± SD RSD (%)
Heart 5.05 100.87 ± 12.35 12.24 102.97 ± 11.06 10.74
10.10 99.96 ± 10.70 10.70 97.19 ± 14.26 14.67
25.25 90.02 ± 9.44 10.49 92.67 ± 12.21 13.18

Liver 5.05 94.93 ± 14.20 14.96 97.94 ± 13.43 13.71
10.10 92.00 ± 10.76 11.70 89.94 ± 10.10 11.23
25.25 95.58 ± 10.45 10.93 100.58 ± 6.20 6.16

Spleen 5.05 93.39 ± 13.76 14.73 95.60 ± 12.14 12.70
10.10 106.57 ± 14.55 13.65 107.84 ± 14.56 13.50
25.25 104.63 ± 5.39 5.15 101.16 ± 5.34 5.28

Lung 8.10 107.38 ± 8.33 7.76 107.83 ± 7.81 7.24
40.50 95.09 ± 12.26 12.79 92.55 ± 9.01 9.74
81.00 101.05 ± 3.99 3.95 102.4 ± 4.14 4.04

Kidney 5.05 96.75 ± 13.77 14.23 95.49 ± 13.13 13.75
10.10 102.34 ± 14.32 13.99 106.46 ± 14.21 13.35
25.25 98.30 ± 10.01 10.18 99.87 ± 10.25 10.26

Brain 5.05 93.82 ± 8.47 9.03 94.06 ± 8.78 9.33
10.10 106.65 ± 13.04 12.23 99.03 ± 12.31 12.43
25.25 100.51 ± 11.27 11.21 98.89 ± 13.15 13.30

Stomach 8.10 94.52 ± 4.07 4.31 97.78 ± 10.50 10.74
40.50 100.84 ± 11.08 10.99 96.03 ± 5.00 5.21
81.00 101.98 ± 6.28 6.16 101.12 ± 7.08 7.00

Uterus 5.05 88.08 ± 10.75 12.20 93.66 ± 11.69 12.48
10.10 89.52 ± 4.55 5.08 89.29 ± 4.69 5.25
25.25 92.2 ± 8.76 9.50 96.70 ± 12.98 13.42

Ovary 5.05 91.09 ± 12.84 14.10 92.83 ± 12.48 13.44
10.10 97.72 ± 13.49 13.80 94.93 ± 14.17 14.93
25.25 95.52 ± 3.65 3.82 96.21 ± 4.98 5.18

Intestine 8.10 97.78 ± 10.52 10.76 99.04 ± 12.78 12.90
40.50 98.43 ± 13.42 13.63 92.34 ± 8.89 9.63
81.00 99.19 ± 12.22 12.32 99.90 ± 12.97 12.98
Table 12.

Recovery and matrix effect study of astragalin in rat tissues (n = 6).

Tissues Spiked (ng/mL) Recovery Matrix effects
Mean (%) ± SD RSD (%) Mean (%) ± SD RSD (%)
Heart 8.10 96.05 ± 10.66 11.10 101.93 ± 13.66 13.40
40.50 93.71 ± 8.42 8.99 95.41 ± 9.36 9.81
81.00 104.43 ± 12.29 11.77 103.7 ± 12.04 11.61

Liver 8.10 115.16 ± 14.23 12.36 119.16 ± 14.67 12.31
40.50 88.31 ± 8.64 9.78 93.07 ± 12.34 13.26
81.00 100.5 ± 5.09 5.06 103.75 ± 6.12 5.90

Spleen 5.05 93.31 ± 9.96 10.67 87.88 ± 11.81 13.44
10.10 118.57 ± 10.60 8.94 112.75 ± 14.93 13.24
25.25 94.99 ± 14.01 14.75 95.34 ± 13.54 14.20

Lung 8.10 109.23 ± 14.92 13.66 108.4 ± 14.06 12.97
40.50 103.39 ± 7.85 7.59 108.74 ± 9.74 8.96
81.00 107.62 ± 6.59 6.12 104.04 ± 8.35 8.03

Kidney 5.05 94.5 ± 12.84 13.59 95.33 ± 11.54 12.11
10.10 99.5 ± 12.95 13.02 104.44 ± 11.11 10.64
25.25 93.96 ± 13.12 13.96 94.98 ± 13.52 14.23

Brain 5.05 93.98 ± 11.22 11.94 97.5 ± 13.92 14.28
10.10 89.98 ± 8.59 9.55 92.55 ± 12.47 13.47
25.25 89.2 ± 8.53 9.56 94.42 ± 11.88 12.58

Stomach 8.10 112.99 ± 14.09 12.47 108.96 ± 14.43 13.24
81.00 108.37 ± 9.73 8.98 105.71 ± 11.12 10.52
162.00 97.94 ± 12.88 13.15 98.35 ± 12.24 12.45

Uterus 5.05 91.17 ± 7.91 8.68 96.04 ± 13.06 13.60
10.10 96.22 ± 11.18 11.62 101.13 ± 14.18 14.02
25.25 100.08 ± 12.77 12.76 103.07 ± 14.14 13.72

Ovary 8.10 108.74 ± 13.50 12.41 116.05 ± 13.30 11.46
40.50 104.44 ± 14.80 14.17 107.02 ± 13.64 12.75
81.00 109.00 ± 14.30 13.12 104.89 ± 14.40 13.73

Intestine 8.10 109.56 ± 14.08 12.85 111.85 ± 14.31 12.79
40.50 95.85 ± 13.47 14.05 96.94 ± 12.25 12.64
81.00 99.52 ± 10.07 10.12 100.56 ± 11.45 11.39
Table 13.

Recovery and matrix effect study of naringin in rat tissues (n = 6).

Tissues Spiked (ng/mL) Recovery Matrix effects
Mean (%) ± SD RSD (%) Mean (%) ± SD RSD (%)
Heart 8.10 110.00 ± 14.19 12.90 117.51 ± 14.62 12.44
405.00 93.51 ± 11.82 12.64 93.89 ± 11.91 12.69
810.00 101.07 ± 8.60 8.51 105.49 ± 8.39 7.95

Liver 12.20 97.87 ± 10.65 10.88 99.51 ± 9.41 9.46
1,220.00 89.61 ± 11.61 12.96 90.30 ± 11.09 12.28
4,880.00 99.40 ± 13.63 13.71 103.70 ± 14.18 13.67

Spleen 8.10 109.60 ± 14.70 13.41 112.52 ± 14.42 12.82
810.00 103.36 ± 8.21 7.94 103.27 ± 8.33 8.07
4,050.00 101.09 ± 14.04 13.89 100.10 ± 14.86 14.85

Lung 8.10 115.98 ± 9.88 8.52 114.91 ± 11.15 9.70
810.00 103.72 ± 13.87 13.37 104.46 ± 13.99 13.39
4,050.00 100.14 ± 13.93 13.91 102.61 ± 12.94 12.61

Kidney 8.10 112.86 ± 13.55 12.01 106.12 ± 6.39 6.02
810.00 108.24 ± 11.67 10.78 106.49 ± 12.47 11.71
4,050.00 96.03 ± 14.21 14.80 100.79 ± 13.41 13.30

Brain 8.10 102.10 ± 14.19 13.90 102.74 ± 13.52 13.16
405.00 102.58 ± 14.19 13.83 99.34 ± 11.32 11.40
810.00 106.80 ± 14.57 13.64 107.01 ± 14.37 13.43

Stomach 8.10 107.26 ± 14.80 13.80 114.20 ± 12.91 11.30
810.00 97.56 ± 12.51 12.82 93.00 ± 7.55 8.12
8,100.00 96.18 ± 7.88 8.19 96.52 ± 7.87 8.15

Uterus 8.10 114.62 ± 8.67 7.56 112.15 ± 12.13 10.82
1,215.00 101.9 ± 14.88 14.60 103.53 ± 14.50 14.01
2,430.00 98.79 ± 13.24 13.40 93.95 ± 10.73 11.42

Ovary 8.10 107.31 ± 13.35 12.44 110.67 ± 12.10 10.93
810.00 105.44 ± 7.65 7.26 107.56 ± 6.27 5.83
4,050.00 101.35 ± 12.01 11.85 97.01 ± 11.43 11.78

Intestine 8.10 104.91 ± 14.63 13.95 110.86 ± 14.79 13.34
810.00 102.29 ± 13.48 13.18 104.20 ± 13.93 13.37
8,100.00 106.06 ± 13.22 12.46 104.55 ± 14.54 13.91
Table 14.

Recovery and matrix effect study of eriodictyol in rat tissues (n = 6).

Tissues Spiked (ng/mL) Recovery Matrix effects
Mean (%) ± SD RSD (%) Mean (%) ± SD RSD (%)
Liver 8.10 106.86 ± 14.59 13.65 109.83 ± 14.69 13.38
40.50 91.41 ± 7.79 8.52 94.49 ± 11.13 11.78
81.00 105.18 ± 14.43 13.72 105.09 ± 14.48 13.78

Spleen 5.05 95.80 ± 11.70 12.21 96.04 ± 11.87 12.36
10.10 113.03 ± 10.54 9.32 115.70 ± 9.70 8.38
25.25 92.38 ± 10.17 11.01 87.52 ± 10.86 12.41

Lung 8.10 109.31 ± 8.93 8.17 108.1 ± 11.23 10.39
40.50 104.59 ± 14.51 13.87 104.43 ± 14.71 14.09
81.00 96.59 ± 9.92 10.27 101.09 ± 14.34 14.19

Stomach 8.10 110.96 ± 14.26 12.85 117.43 ± 12.96 11.04
81.00 99.02 ± 7.86 7.94 102.27 ± 9.24 9.03
162.00 100.60 ± 14.07 13.99 99.81 ± 14.66 14.69

Uterus 5.05 102.46 ± 14.89 14.53 108.36 ± 10.90 10.06
10.10 103.13 ± 13.69 13.27 99.58 ± 11.98 12.03
25.25 89.11 ± 12.68 14.23 91.09 ± 12.37 13.58

Ovary 8.10 106.91 ± 11.88 11.11 109.58 ± 14.54 13.27
40.50 96.92 ± 13.41 13.84 95.40 ± 11.35 11.90
81.00 110.09 ± 8.83 8.02 110.08 ± 8.87 8.06

Intestine 8.10 112.94 ± 12.47 11.04 106.15 ± 14.11 13.29
81.00 96.66 ± 12.21 12.63 101.40 ± 12.07 11.90
162.00 106.34 ± 12.84 12.07 110.76 ± 12.31 11.11
Table 15.

Recovery and matrix effect study of naringenin in rat tissues (n = 6).

Tissues Spiked (ng/mL) Recovery Matrix effects
Mean (%) ± SD RSD (%) Mean (%) ± SD RSD (%)
Heart 8.10 99.16 ± 14.17 14.29 102.00 ± 14.02 13.75
81.00 103.12 ± 11.80 11.44 105.54 ± 8.27 7.84
162.00 99.88 ± 14.63 14.65 101.40 ± 14.36 14.16

Liver 8.10 108.35 ± 14.84 13.70 109.38 ± 14.68 13.42
405.00 108.53 ± 11.75 10.83 107.65 ± 13.09 12.16
810.00 97.99 ± 10.82 11.04 97.58 ± 11.39 11.67

Spleen 8.10 110.94 ± 10.73 9.67 116.25 ± 12.71 10.93
81.00 104.08 ± 8.55 8.21 108.27 ± 5.36 4.95
162.00 92.22 ± 11.76 12.75 95.49 ± 12.40 12.99

Lung 8.10 112.86 ± 13.55 12.01 103.65 ± 10.11 9.75
81.00 99.40 ± 12.26 12.33 100.99 ± 10.33 10.23
162.00 98.08 ± 14.04 14.31 91.96 ± 11.15 12.12

Kidney 8.10 104.57 ± 14.45 13.82 106.32 ± 14.62 13.75
81.00 101.85 ± 12.04 11.82 104.27 ± 9.04 8.67
162.00 105.15 ± 11.94 11.36 103.82 ± 14.64 14.10

Brain 5.05 95.80 ± 12.56 13.11 91.80 ± 13.49 14.69
10.10 108.75 ± 14.63 13.45 110.61 ± 14.02 12.68
25.25 101.59 ± 12.78 12.58 106.93 ± 13.84 12.94

Stomach 8.10 106.79 ± 11.36 10.64 114.59 ± 13.26 11.57
405.00 103.98 ± 14.21 13.67 105.46 ± 13.01 12.34
810.00 105.33 ± 12.86 12.21 98.97 ± 9.74 9.84

Uterus 8.10 109.68 ± 11.56 10.54 105.90 ± 14.62 13.81
81.00 96.79 ± 14.42 14.90 100.89 ± 13.01 12.90
162.00 101.76 ± 14.35 14.10 103.84 ± 14.15 13.63

Ovary 8.10 104.12 ± 14.06 13.50 104.27 ± 13.92 13.35
81.00 102.55 ± 13.60 13.26 102.73 ± 13.50 13.14
162.00 97.63 ± 12.88 13.19 104.93 ± 12.09 11.52

Intestine 8.10 94.69 ± 11.62 12.27 95.33 ± 11.33 11.89
405.00 102.26 ± 13.81 13.50 102.21 ± 13.87 13.57
810.00 95.59 ± 11.24 11.76 95.96 ± 11.07 11.54
Table 16.

Recovery and matrix effect study of kaempferol in rat tissues (n = 6).

Tissues Spiked (ng/mL) Recovery Matrix effects
Mean (%) ± SD RSD (%) Mean (%) ± SD RSD (%)
Liver 8.10 101.65 ± 14.31 14.08 106.96 ± 14.12 13.20
40.50 115.4 ± 14.20 12.31 121.79 ± 10.89 8.94
81.00 102.17 ± 14.31 14.01 104.84 ± 13.72 13.09

Spleen 12.20 93.16 ± 12.41 13.32 86.15 ± 6.77 7.86
91.50 102.12 ± 10.97 10.74 108.20 ± 14.34 13.25
183.00 103.48 ± 14.72 14.22 99.06 ± 10.94 11.04

Lung 5.05 100.12 ± 13.76 13.74 96.20 ± 6.49 6.75
10.10 87.78 ± 6.08 6.93 91.86 ± 13.12 14.28
25.25 94.43 ± 13.83 14.65 90.60 ± 12.32 13.60

Kidney 12.20 89.61 ± 9.00 10.04 90.36 ± 7.52 8.32
42.70 99.04 ± 10.66 10.76 98.81 ± 11.00 11.13
85.40 103.94 ± 7.94 7.64 102.19 ± 10.66 10.43

Stomach 5.05 95.6 ± 14.05 14.70 95.29 ± 14.16 14.86
10.10 105.45 ± 14.18 13.45 103.78 ± 14.59 14.06
25.25 97.72 ± 13.78 14.10 97.81 ± 13.67 13.98

Uterus 5.05 94.69 ± 10.39 10.97 99.45 ± 9.78 9.83
10.10 105.13 ± 13.83 13.16 98.36 ± 10.66 10.84
25.25 95.33 ± 12.51 13.12 93.90 ± 11.54 12.29

Intestine 8.10 104.22 ± 13.70 13.15 101.14 ± 13.81 13.65
121.50 82.72 ± 3.60 4.35 87.29 ± 10.75 12.32
243.00 110.63 ± 14.41 13.03 112.54 ± 14.91 13.25

3.2.5. Stability

The stability of the seven analytes in tissue samples at three different levels of QC samples was performed according to the procedure described above. Results of stability studies shown in Tables 1723 indicate that the seven analytes in tissue samples were stable when stored in auto-sampler (4°C) for 36 h, kept in −20°C for 30 days, and performed three complete freeze/thaw cycles from −20°C at room temperature. No significant degradation occurred during any of the experiment.

Table 17.

Stability of neoeriocitrin in rat tissues (n = 6).

Tissues Spiked (ng/mL) Room temperature Freeze-thaw (−20°C, 3 times) Long term (−20°C, 30 days)
Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%)
Heart 8.10 6.95 ± 0.80 11.51 −14.20 8.15 ± 1.18 14.48 0.62 7.07 ± 1.02 14.43 −12.72
121.50 106.50 ± 6.67 6.26 −12.35 119.40 ± 16.17 13.54 −1.73 111.16 ± 5.83 5.24 −8.51
243.00 254.81 ± 35.08 13.77 4.86 268.16 ± 21.81 8.13 10.35 249.44 ± 25.84 10.36 2.65

Liver 12.20 10.71 ± 0.95 8.87 −12.21 10.78 ± 1.30 12.06 −11.64 10.90 ± 1.52 13.94 −10.66
610.00 596.81 ± 18.63 3.12 −2.16 592.53 ± 11.67 1.97 −2.86 586.32 ± 15.63 2.67 −3.88
3,660.00 3,403.71 ± 343.46 10.09 −7.00 3,313.88 ± 225.54 6.81 −9.46 3,294.94 ± 300.05 9.11 −9.97

Spleen 8.10 9.30 ± 0.68 7.31 14.81 9.23 ± 0.50 5.42 13.95 9.23 ± 0.52 5.63 13.95
810.00 809.27 ± 16.98 2.10 −0.09 798.45 ± 12.24 1.53 −1.43 806.44 ± 14.65 1.82 −0.44
4,050.00 3,696.74 ± 532.72 14.41 −8.72 3,922.39 ± 506.99 12.93 −3.15 3,596.82 ± 365.71 10.17 11.19

Lung 12.20 13.51 ± 0.65 4.81 10.74 11.68 ± 0.63 5.39 −4.26 12.56 ± 1.38 10.99 2.95
1,220.00 1,049.18 ± 151.19 14.41 −14.00 1,064.46 ± 105.31 9.89 −12.75 1,064.00 ± 140.09 13.17 −12.79
4,880.00 4,693.51 ± 174.71 3.72 −3.82 4,655.35 ± 67.79 1.46 −4.60 4,706.89 ± 163.70 3.48 −3.55

Kidney 8.10 9.27 ± 0.41 4.42 14.44 9.29 ± 0.22 2.37 14.69 9.17 ± 0.31 3.38 13.21
121.50 130.10 ± 17.12 13.16 7.08 115.37 ± 7.09 6.15 −5.05 117.29 ± 16.56 14.12 −3.47
243.00 211.85 ± 16.00 7.55 −12.82 268.79 ± 20.77 7.73 10.61 227.65 ± 32.07 14.09 −6.32

Brain 8.10 9.10 ± 0.68 7.47 12.35 8.51 ± 0.98 11.52 5.06 8.51 ± 0.96 11.28 5.06
40.50 36.84 ± 4.11 11.16 −9.04 35.02 ± 5.17 14.76 −13.53 35.89 ± 4.53 12.62 −11.38
81.00 91.02 ± 4.71 5.17 12.37 83.99 ± 6.69 7.97 3.69 86.52 ± 7.86 9.08 6.81

Stomach 8.10 8.79 ± 1.10 12.51 8.52 8.03 ± 0.61 7.60 −0.86 8.42 ± 0.55 6.53 3.95
810.00 849.82 ± 40.54 4.77 4.92 926.35 ± 17.57 1.90 14.36 867.42 ± 68.59 7.91 7.09
4,050.00 4,342.23 ± 411.23 9.47 7.22 4,039.22 ± 283.82 7.03 −0.27 4,301.44 ± 400.81 9.32 6.21

Uterus 8.10 8.51 ± 1.02 11.99 5.06 9.22 ± 0.82 8.89 13.83 8.14 ± 1.14 14.00 0.49
121.50 119.97 ± 12.44 10.37 −1.26 118.34 ± 15.89 13.43 −2.60 125.77 ± 17.07 13.57 3.51
243.00 255.57 ± 29.61 11.59 5.17 211.49 ± 16.06 7.59 −12.97 232.87 ± 16.56 7.11 −4.17

Ovary 8.10 8.06 ± 0.50 6.20 −0.49 7.84 ± 0.84 10.71 −3.21 7.27 ± 0.90 12.38 −10.25
121.50 111.60 ± 15.68 14.05 −8.15 106.87 ± 9.78 9.15 −12.04 111.12 ± 15.83 14.25 −8.54
243.00 230.40 ± 30.17 13.09 −5.19 233.50 ± 27.75 11.88 −3.91 207.73 ± 9.56 4.60 −14.51

Intestine 8.10 8.48 ± 1.10 12.97 4.69 9.05 ± 0.45 4.97 11.73 8.62 ± 1.06 12.30 6.42
810.00 794.00 ± 83.11 10.47 −1.98 772.96 ± 9.97 1.29 −4.57 812.09 ± 62.32 7.67 0.26
4,050.00 4,361.18 ± 410.40 9.41 7.68 4,111.91 ± 456.07 11.09 1.53 4,607.89 ± 16.92 0.37 13.78
Table 18.

Stability of luteolin-7-O-β-D-glucoside in rat tissues (n = 6).

Tissues Spiked (ng/mL) Room temperature Freeze-thaw (−20°C, 3 times) Long term (−20°C, 30 days)
Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%)
Heart 5.05 5.13 ± 0.66 12.87 1.58 5.07 ± 0.59 11.64 0.40 5.05 ± 0.53 10.52 −0.20
10.10 9.36 ± 0.42 4.49 −7.33 10.12 ± 1.09 10.77 0.20 10.00 ± 0.78 7.80 −0.99
25.25 22.45 ± 2.22 9.89 −11.09 25.44 ± 1.48 5.82 0.75 23.44 ± 1.91 8.15 −7.17

Liver 5.05 4.56 ± 0.61 13.38 −9.70 5.07 ± 0.25 4.93 0.40 5.06 ± 0.56 11.07 0.20
10.10 8.77 ± 1.12 12.77 −13.17 9.70 ± 0.72 7.42 −3.96 9.64 ± 0.95 9.85 −4.55
25.25 22.84 ± 1.38 6.04 −9.54 26.21 ± 1.43 5.46 3.80 23.21 ± 2.62 11.29 −8.08

Spleen 5.05 4.37 ± 0.52 11.90 −13.47 5.04 ± 0.33 6.55 −0.20 4.82 ± 0.62 12.86 −4.55
10.10 9.78 ± 1.38 14.11 −3.17 11.58 ± 1.17 10.10 14.65 10.16 ± 1.02 10.04 0.59
25.25 27.07 ± 1.16 4.29 7.21 24.90 ± 1.29 5.18 −1.39 26.63 ± 1.87 7.02 5.47

Lung 8.10 8.82 ± 0.74 8.39 8.89 8.41 ± 0.59 7.02 3.83 8.48 ± 0.85 10.02 4.69
40.50 39.56 ± 5.82 14.71 −2.32 39.03 ± 3.82 9.79 −3.63 39.16± 5.77 14.73 −3.31
81.00 82.50 ± 4.39 5.32 1.85 82.39 ± 2.63 3.19 1.72 82.74 ± 4.20 5.08 2.15

Kidney 5.05 4.65 ± 0.33 7.10 −7.92 5.15 ± 0.50 9.71 1.98 4.95 ± 0.29 5.86 −1.98
10.10 9.15 ± 0.43 4.70 −9.41 11.32 ± 0.67 5.92 12.08 10.23 ± 1.03 10.07 1.29
25.25 23.42 ± 1.98 8.45 −7.25 26.72 ± 1.28 4.79 5.82 25.76 ± 2.08 8.07 2.02

Brain 5.05 5.01 ± 0.29 5.79 −0.79 4.63 ± 0.52 11.23 −8.32 4.88 ± 0.51 10.45 −3.37
10.10 10.90 ± 1.49 13.67 7.92 9.90 ± 1.40 14.14 −1.98 11.15 ± 0.78 7.00 10.40
25.25 26.37 ± 3.36 12.74 4.44 23.03 ± 1.87 8.12 −8.79 24.71 ± 1.25 5.06 −2.14

Stomach 8.10 7.63 ± 0.44 5.77 −5.80 8.25 ± 0.99 12.00 1.85 7.70 ± 0.45 5.84 −4.94
40.50 43.37 ± 4.04 9.32 7.09 37.46 ± 0.73 1.95 −7.51 42.13 ± 5.48 13.01 4.02
81.00 79.72 ± 0.23 0.29 −1.58 83.45 ± 7.55 9.05 3.02 80.64 ± 1.53 1.90 −0.44

Uterus 5.05 4.39 ± 0.13 2.96 −13.07 5.12 ± 0.36 7.03 1.39 4.85 ± 0.40 8.25 −3.96
10.10 9.06 ± 0.64 7.06 −10.30 8.92 ± 0.18 2.02 −11.68 9.19 ± 0.51 5.55 −9.01
25.25 22.05 ± 1.03 4.67 −12.67 26.33 ± 2.74 10.41 4.28 22.84 ± 0.66 2.89 −9.54

Ovary 5.05 4.70 ± 0.61 12.98 −6.93 4.45 ± 0.66 14.83 −11.88 4.73 ± 0.63 13.32 −6.34
10.10 10.18 ± 1.02 10.02 0.79 9.05 ± 0.65 7.18 −10.40 9.31 ± 0.61 6.55 −7.82
25.25 24.37 ± 1.14 4.68 −3.49 24.60 ± 1.54 6.26 −2.57 23.99 ± 1.27 5.29 −4.99

Intestine 8.10 7.82 ± 1.13 14.45 −3.46 8.57 ± 0.95 11.09 5.80 8.13 ± 1.13 13.90 0.37
40.50 42.25 ± 5.88 13.92 4.32 35.91 ± 1.88 5.24 −11.33 40.48 ± 5.17 12.77 −0.05
81.00 78.00 ± 9.32 11.95 −3.70 86.10 ± 10.19 11.84 6.30 83.37 ± 11.64 13.96 2.93
Table 19.

Stability of astragalin in rat tissues (n = 6).

Tissues Spiked (ng/mL) Room temperature Freeze-thaw (−20°C, 3 times) Long term (−20°C, 30 days)
Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%)
Heart 8.10 7.70 ± 0.45 5.84 −4.94 8.47 ± 1.09 12.87 4.57 8.00 ± 0.93 11.63 −1.23
40.50 36.34 ± 1.61 4.43 −10.27 40.78 ± 3.39 8.31 0.69 39.21 ± 4.04 10.30 −3.19
81.00 86.71 ± 12.77 14.73 7.05 82.81 ± 4.93 5.95 2.23 88.04 ± 10.68 12.13 8.69

Liver 8.10 8.40 ± 0.49 5.83 3.70 9.25 ± 0.48 5.19 14.20 9.28 ± 1.20 12.93 14.57
40.50 38.23 ± 1.64 4.29 −5.60 40.11 ± 5.05 12.59 −0.96 37.31 ± 3.82 10.24 −7.88
81.00 78.97 ± 1.50 1.90 −2.51 86.85 ± 4.39 5.05 7.22 79.81 ± 2.36 2.96 −1.47

Spleen 5.05 4.83 ± 0.62 12.84 −4.36 4.67 ± 0.52 11.13 −7.52 5.08 ± 0.25 4.92 0.59
10.10 10.65 ± 0.66 6.20 5.45 10.39 ± 1.08 10.39 2.87 11.05 ± 1.42 12.85 9.41
25.25 23.18 ± 3.01 12.99 −8.20 26.33 ± 2.81 10.67 4.28 25.37 ± 3.04 11.98 0.48

Lung 8.10 9.00 ± 1.11 12.33 11.11 8.58 ± 0.72 8.39 5.93 8.59 ± 0.91 10.59 6.05
40.50 41.43 ± 3.85 9.29 2.30 44.81 ± 4.50 10.04 10.64 43.01 ± 3.91 9.09 6.20
81.00 86.86 ± 7.48 8.61 7.23 83.80 ± 6.72 8.02 3.46 90.25 ± 1.68 1.86 11.42

Kidney 5.05 4.43 ± 0.47 10.61 −12.28 4.90 ± 0.60 12.24 −2.97 4.53 ± 0.53 11.70 −10.30
10.10 9.49 ± 0.84 8.85 −6.04 10.99 ± 1.25 11.37 8.81 10.40 ± 1.02 9.81 2.97
25.25 22.06 ± 1.98 8.98 −12.63 26.65 ± 1.89 7.09 5.54 23.32 ± 3.02 12.95 −7.64

Brain 5.05 4.48 ± 0.59 13.17 −11.29 5.44 ± 0.52 9.56 7.72 4.82 ± 0.42 8.71 −4.55
10.10 9.00 ± 0.76 8.44 −10.89 9.87 ± 1.46 14.79 −2.28 9.59 ± 0.74 7.72 −5.05
25.25 23.04 ± 2.82 12.24 −8.75 23.76 ± 3.54 14.90 −5.90 21.71 ± 0.54 2.49 −14.02

Stomach 8.10 8.49 ± 0.69 8.13 4.81 9.30 ± 1.33 14.30 14.81 9.01 ± 0.59 6.55 11.23
81.00 93.14 ± 4.03 4.33 14.99 79.09 ± 1.25 1.58 −2.36 87.46 ± 7.78 8.90 7.98
162.00 156.45 ± 23.16 14.80 −3.43 152.89 ± 21.65 14.16 −5.62 154.82 ± 22.74 14.69 −4.43

Uterus 5.05 4.37 ± 0.34 7.78 −13.47 5.23 ± 0.49 9.37 3.56 4.52 ± 0.52 11.50 −10.50
10.10 9.18 ± 0.78 8.50 −9.11 11.12 ± 1.40 12.59 10.10 10.23 ± 1.09 10.65 1.29
25.25 23.30 ± 2.05 8.80 −7.72 28.41 ± 1.48 5.21 12.51 26.18 ± 3.07 11.73 3.68

Ovary 8.10 9.05 ± 1.07 11.82 11.73 9.15 ± 1.34 14.64 12.96 8.60 ± 1.19 13.84 6.17
40.50 37.87 ± 4.17 11.01 −6.49 45.76 ± 5.66 12.37 12.99 42.26 ± 6.03 14.27 4.35
81.00 82.74 ± 12.23 14.78 2.15 92.04 ± 8.01 8.70 13.63 92.04 ± 11.52 12.52 13.63

Intestine 8.10 8.28 ± 1.11 13.41 2.22 8.99 ± 0.78 8.68 10.99 8.85 ± 0.81 9.15 9.26
40.50 40.39 ± 5.04 12.48 −0.27 36.13 ± 1.00 2.77 −10.79 39.29 ± 5.25 13.36 −2.99
81.00 83.65 ± 9.85 11.78 3.27 81.48 ± 9.48 11.63 0.59 85.26 ± 7.09 8.32 5.26
Table 20.

Stability of naringin in rat tissues (n = 6).

Tissues Spiked (ng/mL) Room temperature Freeze-thaw (−20°C, 3 times) Long term (−20°C, 30 days)
Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%)
Heart 8.10 8.18 ± 0.99 12.10 0.99 9.31 ± 0.59 6.34 14.94 8.34 ± 1.05 12.59 2.96
405.00 398.76 ± 53.76 13.48 −1.54 363.13 ± 28.56 7.86 −10.34 392.60 ± 57.37 14.61 −3.06
810.00 829.59 ± 77.67 9.36 2.42 842.66 ± 90.17 10.70 4.03 833.28 ± 79.23 9.51 2.87

Liver 12.20 12.40 ± 1.51 12.18 1.64 11.43 ± 0.64 5.60 −6.31 11.77 ± 1.76 14.95 −3.52
1,220.00 1,109.92 ± 162.72 14.66 −9.02 1,056.84 ± 59.00 5.58 −13.37 1,148.25 ± 169.62 14.77 −5.88
4,880.00 4,705.83 ± 702.90 14.94 −3.57 5,273.67 ± 504.56 9.57 8.07 4,969.00 ± 514.84 10.36 1.82

Spleen 8.10 8.85 ± 1.08 12.20 9.26 9.05 ± 1.22 13.48 11.73 8.07 ± 0.85 10.53 −0.37
810.00 801.57 ± 45.20 5.64 −1.04 848.96 ± 85.32 10.05 4.81 822.63 ± 46.56 5.66 1.56
4,050.00 4,143.06 ± 577.07 13.93 2.30 3,865.82 ± 370.26 9.58 −4.55 4,201.39 ± 602.33 14.34 3.74

Lung 8.10 9.26 ± 1.01 10.91 14.32 8.77 ± 0.40 4.56 8.27 9.03 ± 1.06 11.74 11.48
810.00 841.43 ± 64.45 7.66 3.88 849.40 ± 106.55 12.54 4.86 867.33 ± 105.64 12.18 7.08
4,050.00 3,705.01 ± 526.75 14.22 −8.52 4,317.76 ± 550.38 12.75 6.61 3,697.64 ± 514.32 13.91 −8.70

Kidney 8.10 9.15 ± 1.10 12.02 12.96 8.31 ± 0.48 5.78 2.59 9.31 ± 1.02 10.96 14.94
810.00 892.39 ± 40.99 4.59 10.17 834.96 ± 117.60 14.08 3.08 846.20 ± 106.88 12.63 4.47
4,050.00 4,133.40 ± 608.45 14.72 2.06 3,779.16 ± 448.50 11.87 −6.69 3,747.32 ± 516.20 13.78 −7.47

Brain 8.10 8.35 ± 1.01 12.10 3.09 7.92 ± 1.04 13.13 2.22 7.49 ± 0.50 6.68 −7.53
405.00 444.59 ± 47.61 10.71 9.78 385.42 ± 41.47 10.76 −4.83 424.79 ± 47.09 11.09 4.89
810.00 882.19 ± 104.39 11.83 8.91 817.76 ± 120.70 14.76 0.96 810.79 ± 121.05 14.93 0.10

Stomach 8.10 8.47 ± 1.21 14.29 4.57 9.19 ± 1.28 13.93 13.46 7.86 ± 0.52 6.62 −2.96
810.00 790.05 ± 106.47 13.48 −2.46 777.09 ± 71.41 9.19 −4.06 842.24 ± 101.48 12.05 3.98
8,100.00 8,149.70 ± 564.58 6.93 0.61 7,454.36 ± 368.62 4.95 −7.97 7,672.71 ± 291.70 3.80 −5.28

Uterus 8.10 8.96 ± 0.64 7.14 10.62 9.09 ± 1.25 13.75 12.22 9.14 ± 0.94 10.28 12.84
1,215.00 1,155.91 ± 151.48 13.10 −4.86 1,358.76 ± 84.48 6.22 11.83 1,266.07 ± 11.09 0.88 4.20
2,430.00 2,461.22 ± 348.52 14.16 1.28 2,262.54 ± 87.25 3.86 −6.89 2,330.98 ± 332.29 14.26 −4.07

Ovary 8.10 8.06 ± 1.07 13.28 −0.49 9.16 ± 0.74 8.08 13.09 7.97 ± 1.05 13.17 −1.60
810.00 820.47 ± 26.50 3.23 1.29 895.06 ± 54.93 6.14 10.50 827.50 ± 32.71 3.95 2.16
4,050.00 3,954.66 ± 490.84 12.41 −2.35 4,095.99 ± 558.04 13.62 1.14 4,080.56 ± 377.08 9.24 0.75

Intestine 8.10 8.19 ± 0.90 10.99 1.11 9.30 ± 1.24 13.33 14.81 7.63 ± 0.13 1.70 −5.80
810.00 818.79 ± 115.79 14.14 1.09 877.24 ± 105.43 12.02 8.30 845.43 ± 80.79 9.56 4.37
8,100.00 8,351.44 ± 1,228.10 14.71 3.10 8,229.70 ± 1,151.14 13.99 1.60 8,818.55 ± 1,318.14 14.95 8.87
Table 21.

Stability of eriodictyol in rat tissues (n = 6).

Tissues Spiked (ng/mL) Room temperature Freeze-thaw (−20°C, 3 times) Long term (−20°C, 30 days)
Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%)
Liver 8.10 8.74 ± 0.86 9.84 7.90 9.07 ± 1.31 14.44 11.98 7.90 ± 0.98 12.41 −2.47
40.50 35.14 ± 2.55 7.26 −13.23 41.26 ± 2.48 6.01 1.88 37.37 ± 2.39 6.40 −7.73
81.00 86.70 ± 8.92 10.29 7.04 81.90 ± 12.13 14.81 1.11 91.19 ± 9.55 10.47 12.58

Spleen 5.05 4.58 ± 0.65 14.19 −9.31 5.23 ± 0.16 3.06 3.56 4.82 ± 0.61 12.66 −4.55
10.10 11.14 ± 1.33 11.94 10.30 10.87 ± 0.46 4.23 7.62 11.35 ± 1.08 9.52 12.38
25.25 24.57 ± 2.36 9.61 −2.69 21.75 ± 1.80 8.28 −13.86 24.87 ± 1.86 7.48 −1.50

Lung 8.10 8.67 ± 0.94 10.84 7.04 8.52 ± 1.06 12.44 5.19 8.94 ± 0.99 11.07 10.37
40.50 44.21 ± 6.02 13.62 9.16 38.47 ± 3.91 10.16 −5.01 40.58 ± 5.08 12.52 0.20
81.00 74.39 ± 7.67 10.31 −8.16 88.31 ± 8.37 9.48 9.02 81.83 ± 5.22 6.38 1.02

Stomach 8.10 8.07 ± 0.83 10.29 −0.37 9.21 ± 0.21 2.28 13.70 8.95 ± 0.94 10.50 10.49
81.00 76.31 ± 4.44 5.82 −5.79 87.52 ± 3.29 3.76 8.05 80.47 ± 3.35 4.16 −0.65
162.00 156.23 ± 14.25 9.12 −3.56 163.44 ± 23.11 14.14 0.89 165.97 ± 24.01 14.47 2.45

Uterus 5.05 5.34 ± 0.79 14.79 5.74 5.15 ± 0.41 7.96 1.98 4.96 ± 0.67 13.51 −1.78
10.10 10.77 ± 1.36 12.63 6.63 9.56 ± 1.35 14.12 −5.35 10.42 ± 0.87 8.35 3.17
25.25 24.07 ± 3.23 13.42 −4.67 22.30 ± 2.21 9.91 −11.68 22.60 ± 3.35 14.82 −10.50

Ovary 8.10 8.99 ± 1.10 12.24 10.99 8.83 ± 1.25 14.16 9.01 9.25 ± 0.73 7.89 14.20
40.50 37.31 ± 1.78 4.77 −7.88 39.47 ± 5.77 14.62 −2.54 40.46 ± 6.01 14.85 −0.10
81.00 89.65 ± 10.06 11.22 10.68 84.97 ± 6.08 7.16 4.90 86.94 ± 8.45 9.72 7.33

Intestine 8.10 8.73 ± 1.15 13.17 7.78 8.95 ± 1.15 12.85 10.49 9.31 ± 1.23 13.21 14.94
81.00 82.71 ± 11.00 13.30 2.11 77.65 ± 10.42 13.42 −4.14 77.44 ± 10.21 13.18 −4.40
162.00 159.30 ± 2.85 1.79 −1.67 181.74 ± 15.06 8.29 12.19 164.51 ± 10.80 6.56 1.55
Table 22.

Stability of naringenin in rat tissues (n = 6).

Tissues Spiked (ng/mL) Room temperature Freeze-thaw (−20°C, 3 times) Long term (−20°C, 30 days)
Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%)
Heart 8.10 8.04 ± 1.04 12.94 −0.74 8.24 ± 1.17 14.20 1.73 8.00 ± 1.08 13.50 −1.23
81.00 81.52 ± 11.82 14.50 0.64 84.33 ± 6.52 7.73 4.11 77.37 ± 6.28 8.12 −4.48
162.00 151.00 ± 20.37 13.49 −6.79 169.65 ± 21.47 12.66 4.72 171.11 ± 25.44 14.87 5.62

Liver 8.10 8.00 ± 0.80 10.00 −1.23 9.27 ± 1.32 14.24 14.44 8.55 ± 1.25 14.62 5.56
405.00 418.93 ± 47.87 11.43 3.44 436.27 ± 64.51 14.79 7.72 434.87 ± 44.93 10.33 7.38
810.00 778.74 ± 112.79 14.48 −3.86 771.71 ± 87.80 11.38 −4.73 734.04 ± 37.39 5.09 −9.38

Spleen 8.10 8.58 ± 0.70 8.16 5.93 9.22 ± 0.83 9.00 13.83 8.87 ± 1.19 13.42 9.51
81.00 80.48 ± 6.41 7.96 −0.64 90.38 ± 0.78 0.86 11.58 83.50 ± 8.26 9.89 3.09
162.00 139.60 ± 17.83 12.77 −13.83 165.50 ± 7.38 4.46 2.16 156.36 ± 14.57 9.32 −3.48

Lung 8.10 9.15 ± 1.10 12.02 12.96 7.98 ± 0.83 10.40 −1.48 9.31 ± 1.22 13.10 14.98
81.00 74.57 ± 7.11 9.53 −7.94 84.78 ± 8.89 10.49 4.67 79.09 ± 8.84 11.18 −2.36
162.00 156.47 ± 22.72 14.52 −3.41 154.67 ± 21.84 14.12 −4.52 167.06 ± 23.04 13.79 3.12

Kidney 8.10 8.45 ± 1.14 13.49 4.32 8.42 ± 1.06 12.59 3.95 8.13 ± 1.09 13.41 0.37
81.00 77.29 ± 9.32 12.06 −4.58 86.85 ± 6.12 7.05 7.22 83.16 ± 11.44 13.76 2.67
162.00 167.81 ± 24.47 14.58 3.59 159.11 ± 23.36 14.68 −1.78 162.72 ± 22.74 13.97 0.44

Brain 5.05 4.56 ± 0.49 10.75 −9.70 4.88 ± 0.64 13.11 −3.37 4.71 ± 0.42 8.92 −6.73
10.10 11.45 ± 1.03 9.00 13.37 10.80 ± 0.98 9.07 6.93 10.81 ± 1.45 13.41 7.03
25.25 23.97 ± 2.89 12.06 −5.07 28.86 ± 1.83 6.34 14.30 25.78 ± 1.99 7.72 2.10

Stomach 8.10 8.16 ± 0.84 10.29 0.74 8.84 ± 0.84 9.50 9.14 8.35 ± 1.16 13.89 3.09
405.00 407.95 ± 57.80 14.17 0.73 417.68 ± 62.09 14.87 3.13 435.78 ± 65.10 14.94 7.60
810.00 843.25 ± 105.05 12.46 4.10 823.51 ± 95.20 11.56 1.67 881.58 ± 126.68 14.37 8.84

Uterus 8.10 9.06 ± 0.83 9.16 11.85 7.79 ± 0.82 10.53 −3.83 8.81 ± 1.28 14.53 8.77
81.00 73.81 ± 5.18 7.02 −8.88 85.29 ± 11.93 13.99 5.30 73.36 ± 5.25 7.16 −9.43
162.00 153.95 ± 20.86 13.55 −4.97 172.19 ± 17.57 10.20 6.29 154.24 ± 22.37 14.50 −4.79

Ovary 8.10 7.86 ± 0.67 8.52 −2.96 8.73 ± 1.17 13.40 7.78 7.76 ± 0.50 6.44 −4.20
81.00 78.53 ± 11.16 14.21 −3.05 86.02 ± 9.25 10.75 6.20 76.30 ± 7.87 10.31 −5.80
162.00 144.08 ± 10.08 7.00 −11.06 183.49 ± 8.80 4.80 13.27 156.39 ± 23.1 14.77 −3.46

Intestine 8.10 7.69 ± 1.01 13.13 −5.06 7.59 ± 0.54 7.11 −6.30 8.16 ± 0.93 11.40 0.74
405.00 409.72 ± 54.55 13.31 1.17 399.15 ± 58.51 14.66 −1.44 434.72 ± 60.96 14.02 7.34
810.00 823.39 ± 83.78 10.18 1.65 717.09 ± 36.44 5.08 −11.47 748.90 ± 78.81 10.52 −7.54
Table 23.

Stability of kaempferol in rat tissues (n = 6).

Tissues Spiked (ng/mL) Room temperature Freeze-thaw (−20°C, 3 times) Long term (−20°C, 30 days)
Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%) Mean ± SD RSD (%) RE (%)
Liver 8.10 8.39 ± 1.60 14.04 3.54 8.62 ± 1.09 12.69 6.46 8.57 ± 1.42 14.62 5.76
40.50 43.77 ± 9.22 13.06 8.08 50.17 ± 2.46 4.90 13.88 46.07 ± 9.62 14.87 13.75
81.00 83.39 ± 13.38 14.35 2.95 82.41 ± 11.32 13.74 1.74 88.11 ± 13.51 14.33 8.78

Spleen 12.20 11.80 ± 1.91 14.15 −3.28 10.33 ± 0.84 8.09 −14.36 12.19 ± 1.43 11.75 −0.11
91.50 89.37 ± 5.89 6.59 −2.32 104.78 ± 13.69 13.06 14.52 87.15 ± 2.32 2.66 −4.76
183.00 189.62 ± 32.89 14.35 3.62 188.06 ± 24.01 12.77 2.77 201.14 ± 33.04 14.43 9.91

Lung 5.05 5.26 ± 0.82 14.68 4.16 4.91 ± 0.45 9.19 −2.84 5.11 ± 0.97 14.94 1.19
10.10 8.89 ± 0.72 8.05 −11.98 9.79 ± 1.73 14.71 −3.07 9.07 ± 0.74 8.20 −10.23
25.25 23.20 ± 5.65 14.34 −8.11 24.29 ± 3.55 14.60 −3.79 24.46 ± 6.43 14.31 −3.13

Kidney 12.20 10.56 ± 1.22 11.55 −13.42 10.86 ± 1.26 11.55 −10.96 10.39 ± 1.07 10.34 −14.86
42.70 41.76 ± 4.97 11.90 −2.20 40.96 ± 5.41 13.21 −4.07 43.77 ± 5.68 12.99 2.51
85.40 86.58 ± 7.17 8.28 1.39 86.17 ± 11.23 13.04 0.90 91.18 ± 8.09 8.88 6.76

Stomach 5.05 4.77 ± 1.03 11.50 −5.48 4.86 ± 0.38 7.85 −3.83 5.05 ± 0.64 12.74 −0.07
10.10 11.62 ± 1.09 9.42 14.02 9.41 ± 0.37 3.95 −6.80 10.40 ± 1.12 10.79 2.94
25.25 24.02 ± 2.30 9.55 −4.87 24.27 ± 4.81 14.82 −3.89 25.50 ± 4.23 14.58 1.00

Uterus 5.05 4.42 ± 0.24 5.35 −12.48 5.37 ± 0.09 1.69 6.27 4.74 ± 0.51 10.80 −6.20
10.10 11.14 ± 1.60 14.33 10.26 9.57 ± 0.75 7.87 −5.25 10.75 ± 1.57 14.60 6.40
25.25 22.74 ± 3.64 14.02 −9.95 25.59 ± 0.85 3.31 1.36 25.10 ± 2.16 8.61 −0.58

Intestine 8.10 8.36 ± 1.13 13.49 3.17 8.27 ± 1.20 14.53 2.06 8.54 ± 1.33 14.62 5.43
121.50 97.69 ± 2.61 2.67 −14.60 112.52 ± 13.53 12.03 −7.39 100.47 ± 2.96 2.95 −14.31
243.00 241.99 ± 28.92 11.95 −0.42 286.61 ± 39.49 13.78 14.95 265.03 ± 42.79 14.15 9.07

3.3. Tissue Distribution Study

The tissue distribution of the seven analytes was investigated in 8-month-old and 18-month-old SD rats at 0, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 h after oral administration of TFDR by collecting tissues including the heart, liver, spleen, lung, kidney, stomach, brain, uterus, ovary, and small intestine. The tendency graphs of the seven analytes in various SD rat tissues are shown in Figure 3. The concentrations of seven analytes in 8-month-old and 18-month-old rats' various tissues after oral administration of TFDR are shown in Tables 24 and 25, respectively. Luteolin was not detected in tissues. It may be that the concentration of luteolin in tissues was too low to reach the limit of detection. The results of the present study indicated that seven analytes underwent a rapid and wide distribution into tissues.

Figure 3.

Figure 3

Concentrations of seven analytes in rat tissues at 0.25, 0.5, 1, 2, 4, 8, and 12 h after oral administration of TFDR in 8-month-old rats (left) and 18-month-old rats (right).

Table 24.

Tissue concentrations of seven analytes at different times after oral administration in 8-month-old rats (ng/g, n = 5).

Analytes Tissue 0.25 h 0.5 h 1 h 2 h 4 h 8 h 12 h
Neoeriocitrin Heart 39.18 ± 10.58 222.17 ± 35.38 173.93 ± 32.14 121.81 ± 30.37 68.13 ± 16.59 9.22 ± 1.68 0.00
Liver 31.86 ± 7.17 501.02 ± 59.13 3,247.80 ± 413.47 2,201.25 ± 211.27 355.59 ± 119.14 167.65 ± 49.30 14.25 ± 6.75
Spleen 102.90 ± 13.98 2,190.70 ± 345.97 8,008.91 ± 715.34 1,397.10 ± 286.06 159.13 ± 56.30 36.68 ± 34.51 7.50 ± 1.74
Lung 1,119.98 ± 146.91 6,039.56 ± 279.40 7,837.99 ± 493.16 5,080.60 ± 431.81 695.30 ± 107.71 34.26 ± 8.21 0.00
Kidney 134.72 ± 9.14 414.94 ± 60.69 257.50 ± 75.86 112.65 ± 30.13 29.32 ± 9.44 7.65 ± 4.81 0.00
Brain 13.32 ± 2.84 25.03 ± 2.27 34.04 ± 6.39 8.31 ± 0.92 4.45 ± 1.87 0.00 0.00
Stomach 4,061.88 ± 312.91 7,324.59 ± 397.44 3,775.38 ± 465.61 1,513.07 ± 264.13 502.61 ± 189.18 25.85 ± 5.70 0.00
Uterus 75.22 ± 10.79 156.79 ± 16.29 251.62 ± 35.33 70.32 ± 13.94 26.97 ± 4.04 7.26 ± 2.46 0.00
Ovary 103.83 ± 17.25 162.03 ± 24.58 251.99 ± 32.24 146.23 ± 16.34 12.27 ± 6.13 0.00 0.00
Intestine 188.58 ± 45.77 4,818.76 ± 299.03 8,133.84 ± 581.81 993.61 ± 114.13 781.08 ± 121.90 163.04 ± 32.57 0.00

Luteolin-7-O-β-D-glucoside Heart 9.58 ± 2.01 20.71 ± 3.14 15.06 ± 2.10 8.87 ± 2.14 3.27 ± 1.06 0.00 0.00
Liver 7.44 ± 1.19 21.80 ± 4.17 12.38 ± 2.34 6.65 ± 1.14 3.48 ± 2.53 0.00 0.00
Spleen 4.11 ± 2.23 7.69 ± 3.58 38.03 ± 7.51 15.62 ± 6.06 7.51 ± 2.77 2.48 ± 1.85 0.00
Lung 8.82 ± 1.26 24.53 ± 2.02 51.71 ± 3.02 20.08 ± 4.13 7.69 ± 2.51 2.82 ± 3.26 0.00
Kidney 2.43 ± 1.72 4.81 ± 2.61 8.44 ± 6.55 32.29 ± 9.01 17.40 ± 5.39 2.88 ± 1.44 0.00
Brain 2.14 ± 0.87 13.17 ± 1.79 7.14 ± 0.92 1.95 ± 0.74 1.05 ± 0.52 0.00 0.00
Stomach 70.44 ± 7.01 92.66 ± 11.08 64.82 ± 5.00 46.88 ± 9.75 31.71 ± 6.82 3.79 ± 2.90 0.00
Uterus 8.90 ± 0.95 9.65 ± 0.59 22.33 ± 4.67 6.52 ± 2.08 3.29 ± 2.27 0.00 0.00
Ovary 6.09 ± 1.20 9.94 ± 3.64 17.25 ± 6.60 20.16 ± 5.62 4.65 ± 2.56 0.00 0.00
Intestine 21.13 ± 3.16 87.42 ± 11.09 68.78 ± 8.31 40.51 ± 7.63 21.03 ± 7.04 2.71 ± 1.35 0.00

Astragalin Heart 5.16 ± 2.00 44.98 ± 13.39 21.10 ± 3.34 9.17 ± 1.97 4.55 ± 1.51 1.34 ± 0.67 0.00
Liver 9.55 ± 1.67 24.38 ± 5.93 63.85 ± 10.04 22.40 ± 3.22 8.48 ± 3.52 4.53 ± 3.04 0.00
Spleen 4.82 ± 0.94 11.88 ± 2.34 23.04 ± 3.18 41.29 ± 6.27 8.69 ± 4.48 3.32 ± 2.61 0.00
Lung 9.26 ± 1.67 12.71 ± 1.47 44.28 ± 6.91 31.32 ± 4.41 15.46 ± 5.84 8.06 ± 2.45 2.04 ± 1.02
Kidney 6.04 ± 1.45 8.64 ± 2.33 13.76 ± 1.92 19.11 ± 1.64 7.87 ± 2.20 2.70 ± 2.12 0.00
Brain 5.41 ± 1.71 6.08 ± 1.44 27.72 ± 7.78 14.98 ± 1.23 0.13 ± 0.07 0.00 0.00
Stomach 54.36 ± 13.29 92.09 ± 5.08 124.20 ± 20.11 242.33 ± 28.28 90.80 ± 5.12 12.87 ± 3.39 0.00
Uterus 9.17 ± 1.60 12.51 ± 1.46 36.06 ± 14.35 21.44 ± 8.70 8.11 ± 1.98 4.13 ± 2.88 0.00
Ovary 16.09 ± 2.13 41.80 ± 7.89 56.24 ± 5.64 35.79 ± 7.01 6.55 ± 2.67 1.27 ± 0.64 0.00
Intestine 9.08 ± 2.60 13.45 ± 5.10 46.33 ± 14.85 84.05 ± 6.62 54.11 ± 16.00 0.00 0.00

Naringin Heart 24.05 ± 3.55 305.07 ± 23.30 802.23 ± 48.96 95.19 ± 19.18 25.10 ± 8.37 18.89 ± 6.74 4.22 ± 3.00
Liver 3,100.99 ± 329.24 6,844.61 ± 394.09 8,990.54 ± 645.09 4,696.73 ± 787.00 2,309.32 ± 361.78 4,316.78 ± 750.95 87.26 ± 61.30
Spleen 1,033.31 ± 123.04 2,117.77 ± 261.76 8,347.29 ± 550.68 7,318.88 ± 584.70 4,566.69 ± 415.28 161.26 ± 73.58 65.26 ± 20.78
Lung 2,403.72 ± 542.57 6,136.89 ± 597.95 8,028.23 ± 577.45 4,758.34 ± 388.04 2,218.44 ± 480.61 261.11 ± 187.44 72.21 ± 44.57
Kidney 3,898.03 ± 305.12 5,952.40 ± 564.86 6,815.11 ± 427.58 3,831.32 ± 409.31 997.11 ± 113.99 182.31 ± 72.30 10.28 ± 2.11
Brain 254.15 ± 31.88 914.44 ± 114.98 769.77 ± 106.65 632.54 ± 64.55 403.25 ± 46.45 163.38 ± 36.62 13.74 ± 11.25
Stomach 1,089.48 ± 158.52 2,523.96 ± 367.74 4,874.73 ± 712.92 6,845.44 ± 660.93 1,957.66 ± 275.96 205.47 ± 86.57 6.92 ± 3.84
Uterus 1,797.02 ± 178.68 3,515.04 ± 532.80 4,022.84 ± 195.00 3,052.92 ± 310.56 1,130.50 ± 192.81 2,476.23 ± 917.77 38.34 ± 29.09
Ovary 3,884.52 ± 446.17 5,049.08 ± 241.23 8,319.83 ± 564.53 2,283.59 ± 417.38 1,434.68 ± 357.23 113.37 ± 34.10 0.00
Intestine 1,192.96 ± 191.76 4,933.79 ± 803.89 8,510.36 ± 952.27 11,753.34 ± 1,203.70 1,465.91 ± 469.36 448.75 ± 196.23 0.00

Eriodictyol Liver 19.37 ± 2.97 23.76 ± 2.79 144.70 ± 20.72 71.92 ± 16.12 136.87 ± 30.56 96.07 ± 48.74 0.00
Spleen 0.00 4.29 ± 1.55 19.26 ± 1.84 26.20 ± 4.64 2.11 ± 0.23 0.00 0.00
Lung 49.46 ± 6.08 30.50 ± 7.01 19.56 ± 2.94 8.70 ± 1.76 3.87 ± 2.91 0.00 0.00
Stomach 58.57 ± 7.99 89.49 ± 17.62 105.23 ± 20.57 148.36 ± 15.79 80.59 ± 7.28 13.04 ± 4.34 0.00
Uterus 8.46 ± 1.82 16.52 ± 4.19 33.10 ± 4.66 8.25 ± 5.11 1.08 ± 0.06 0.00 0.00
Ovary 6.21 ± 0.72 10.50 ± 1.41 32.09 ± 2.87 10.05 ± 1.43 4.08 ± 1.95 0.00 0.00
Intestine 37.69 ± 12.93 138.00 ± 61.75 209.76 ± 71.61 69.79 ± 20.12 26.10 ± 9.96 6.25 ± 1.06 0.00

Naringenin Heart 2.45 ± 0.78 5.15 ± 1.12 7.68 ± 1.07 21.54 ± 3.80 29.00 ± 5.82 182.90 ± 11.46 0.00
Liver 17.88 ± 2.93 31.73 ± 6.68 46.63 ± 5.29 155.17 ± 25.16 761.78 ± 99.66 837.21 ± 69.13 23.80 ± 12.62
Spleen 11.50 ± 1.36 16.51 ± 3.35 30.39 ± 11.29 165.29 ± 11.28 97.20 ± 18.16 57.48 ± 13.95 11.16 ± 9.47
Lung 11.66 ± 1.74 37.15 ± 6.87 63.24 ± 4.93 53.05 ± 7.00 48.79 ± 12.05 101.33 ± 17.69 3.31 ± 0.63
Kidney 8.65 ± 2.02 39.65 ± 4.97 54.99 ± 7.07 48.80 ± 7.84 53.29 ± 8.58 103.53 ± 14.66 0.00
Brain 3.27 ± 1.49 9.39 ± 3.66 5.01 ± 1.91 0.80 ± 0.61 0.00 0.00 0.00
Stomach 234.16 ± 20.86 313.03 ± 55.49 369.35 ± 40.89 622.55 ± 25.86 435.45 ± 91.57 162.98 ± 18.45 8.57 ± 1.15
Uterus 17.51 ± 3.47 24.28 ± 4.26 141.20 ± 18.48 79.43 ± 14.57 182.01 ± 20.39 118.06 ± 33.90 8.92 ± 1.85
Ovary 16.78 ± 5.55 28.05 ± 7.04 132.19 ± 34.53 75.75 ± 9.82 185.35 ± 10.12 137.40 ± 23.25 0.00
Intestine 13.35 ± 2.46 31.49 ± 14.73 140.07 ± 31.41 60.03 ± 15.27 144.57 ± 40.01 98.08 ± 45.70 0.00

Kaempferol Liver 0.67 ± 0.35 11.53 ± 4.46 68.82 ± 13.01 49.80 ± 14.43 17.44 ± 5.63 2.51 ± 1.60 0.00
Spleen 0.00 9.67 ± 3.02 182.98 ± 17.07 22.46 ± 3.82 16.06 ± 6.56 8.96 ± 7.29 0.00
Lung 11.40 ± 1.07 24.08 ± 2.27 29.52 ± 1.85 19.73 ± 1.14 8.78 ± 2.16 0.87 ± 0.74 0.00
Kidney 16.19 ± 3.45 24.34 ± 5.27 31.90 ± 5.32 55.28 ± 5.99 22.71 ± 4.80 0.00 0.00
Stomach 17.25 ± 1.93 24.54 ± 2.69 39.83 ± 13.60 43.81 ± 5.36 21.79 ± 7.01 4.95 ± 3.58 0.00
Uterus 3.36 ± 1.70 6.19 ± 0.85 24.01 ± 3.45 18.35 ± 3.34 12.50 ± 1.60 0.00 0.00
Intestine 44.75 ± 8.17 80.12 ± 14.32 405.27 ± 37.64 348.26 ± 12.33 310.25 ± 42.39 39.37 ± 8.12 0.00

Table 25.

Tissue concentrations of seven analytes at different times after oral administration in 18-month-old rats (ng/g, n = 5).

Analytes Tissue 0.25 h 0.5 h 1 h 2 h 4 h 8 h 12 h
Neoeriocitrin Heart 31.73 ± 3.60 189.07 ± 21.88 164.81 ± 17.36 101.18 ± 12.35 77.21 ± 5.02 25.17 ± 2.90 0.00
Liver 16.96 ± 1.53 401.00 ± 31.39 2,431.18 ± 217.03 1,571.02 ± 164.80 677.16 ± 48.76 305.28 ± 35.76 0.00
Spleen 230.11 ± 15.95 2,006.98 ± 117.28 5,970.17 ± 737.71 2,543.47 ± 175.93 1,114.32 ± 88.74 377.12 ± 35.87 0.00
Lung 1,927.71 ± 172.26 5,092.49 ± 130.22 6,223.83 ± 597.97 4,985.02 ± 490.80 1,463.71 ± 179.74 372.35 ± 38.97 0.00
Kidney 97.28 ± 8.59 387.12 ± 44.81 235.05 ± 27.59 127.05 ± 7.19 66.06 ± 8.01 13.80 ± 1.59 0.00
Brain 8.15 ± 0.75 20.59 ± 1.42 24.98 ± 1.99 7.41 ± 0.70 6.47 ± 0.47 0.00 0.00
Stomach 3,632.23 ± 336.19 5,552.27 ± 384.05 3,964.81 ± 315.74 2,299.33 ± 278.83 1,039.50 ± 119.57 585.36 ± 46.62 68.88 ± 6.55
Uterus 49.22 ± 4.45 106.19 ± 8.31 180.98 ± 16.16 78.08 ± 8.19 40.89 ± 2.94 17.19 ± 2.02 0.00
Ovary 78.22 ± 4.57 111.62 ± 10.33 170.29 ± 11.78 138.69 ± 11.04 64.70 ± 6.15 41.51 ± 3.00 0.00
Intestine 1,646.14 ± 96.19 4,254.15 ± 393.76 6,236.26 ± 431.37 3,118.61 ± 248.35 1,426.29 ± 102.70 463.22 ± 54.26 0.00

Luteolin- 7-O-β-D-glucoside Heart 10.88 ± 1.03 49.05 ± 4.38 29.95 ± 0.77 12.27 ± 1.17 6.94 ± 0.68 6.38 ± 0.78 0.00
Liver 6.98 ± 0.48 21.34 ± 1.25 48.17 ± 4.46 27.24 ± 1.18 16.49 ± 1.31 9.14 ± 2.54 3.79 ± 3.17
Spleen 4.95 ± 0.36 12.27 ± 0.69 22.73 ± 2.76 38.76 ± 4.46 14.50 ± 1.15 5.44 ± 0.52 0.00
Lung 8.68 ± 0.64 11.67 ± 0.66 24.51 ± 2.97 34.10 ± 3.92 13.35 ± 1.63 7.91 ± 0.51 0.00
Kidney 4.68 ± 0.37 6.35 ± 0.57 11.03 ± 1.16 15.63 ± 1.08 9.87 ± 0.79 6.05 ± 0.58 0.00
Brain 3.80 ± 0.34 9.14 ± 1.06 25.02 ± 2.94 12.37 ± 0.95 5.11 ± 0.57 0.00 0.00
Stomach 39.57 ± 4.58 75.86 ± 8.90 130.26 ± 10.04 205.52 ± 22.86 136.00 ± 13.96 26.54 ± 3.51 14.21 ± 1.59
Uterus 7.72 ± 0.74 10.10 ± 0.99 24.21 ± 2.97 19.84 ± 1.58 12.60 ± 1.20 6.98 ± 0.51 0.00
Ovary 14.85 ± 1.16 41.55 ± 3.71 38.08 ± 3.99 30.21 ± 3.97 11.18 ± 1.15 0.00 0.00
Intestine 7.72 ± 0.69 8.97 ± 0.23 38.79 ± 3.71 701.13 ± 6.90 48.59 ± 5.89 14.75 ± 1.70 0.00

Astragalin Heart 6.39 ± 0.67 21.86 ± 2.21 13.27 ± 1.19 10.78 ± 0.84 5.80 ± 0.52 4.42 ± 0.50 0.00
Liver 6.93 ± 0.61 18.64 ± 2.16 14.38 ± 1.69 9.51 ± 0.73 7.18 ± 0.80 5.31 ± 1.13 0.00
Spleen 2.77 ± 0.16 4.42 ± 0.41 30.81 ± 2.13 17.57 ± 1.40 9.09 ± 0.86 6.04 ± 0.44 0.00
Lung 7.85 ± 0.79 20.13 ± 1.81 39.92 ± 3.12 17.98 ± 1.62 10.30 ± 1.16 7.32 ± 0.82 0.00
Kidney 2.45 ± 0.17 3.57 ± 0.21 10.31 ± 0.95 34.03 ± 2.35 16.68 ± 1.33 8.76 ± 0.83 3.41 ± 0.25
Brain 3.23 ± 0.37 10.09 ± 1.17 7.11 ± 0.75 3.84 ± 0.47 2.14 ± 0.14 0.00 0.00
Stomach 50.47 ± 5.31 73.23 ± 9.63 124.20 ± 20.11 242.33 ± 28.28 90.80 ± 5.12 12.87 ± 3.39 0.00
Uterus 7.05 ± 0.74 8.07 ± 1.06 15.35 ± 1.58 10.07 ± 1.33 6.87 ± 0.62 4.08 ± 0.46 0.00
Ovary 5.59 ± 0.59 9.39 ± 1.23 14.14 ± 1.45 17.47 ± 1.79 9.13 ± 1.21 4.01 ± 0.45 0.00
Intestine 17.15 ± 1.00 73.74 ± 6.83 53.74 ± 3.72 35.12 ± 4.04 15.60 ± 1.24 7.20 ± 0.68 0.00

Naringin Heart 15.87 ± 2.49 201.48 ± 20.58 643.80 ± 91.40 99.05 ± 15.19 40.88 ± 2.88 22.64 ± 2.88 10.91 ± 1.45
Liver 2,848.51 ± 428.98 4,590.53 ± 744.43 7,219.96 ± 1,059.27 3,393.97 ± 490.96 1,933.20 ± 259.73 4,047.07 ± 309.31 90.95 ± 10.55
Spleen 827.46 ± 77.63 1,997.58 ± 151.10 7,005.53 ± 555.82 4,646.08 ± 509.30 3,556.25 ± 666.72 1,077.91 ± 166.30 187.62 ± 28.35
Lung 2,467.96 ± 219.09 4,314.82 ± 373.65 5,985.15 ± 291.65 3,011.26 ± 247.62 2,118.82 ± 171.12 280.11 ± 33.42 83.92 ± 10.13
Kidney 3,004.22 ± 241.98 5,728.09 ± 367.43 7,354.37 ± 678.80 3,414.98 ± 295.76 1,578.24 ± 75.40 621.79 ± 17.60 130.97 ± 3.45
Brain 180.55 ± 11.86 844.75 ± 43.48 756.89 ± 133.87 500.91 ± 16.24 371.38 ± 20.03 127.58 ± 7.22 42.62 ± 2.27
Stomach 934.78 ± 63.59 2,648.34 ± 29.62 11,647.56 ± 856.48 5,195.02 ± 398.77 2,449.35 ± 120.89 266.57 ± 18.89 8.42 ± 0.65
Uterus 1,367.90 ± 24.22 3,012.12 ± 11.46 3,367.69 ± 178.65 2,330.25 ± 166.02 1,300.67 ± 153.39 2,066.60 ± 132.32 71.21 ± 3.31
Ovary 3,842.79 ± 127.02 4,546.92 ± 322.21 6,362.25 ± 267.28 17,813.64 ± 785.27 17,192.38 ± 9,967.81 363.64 ± 29.11 31.74 ± 2.55
Intestine 673.87 ± 58.98 3,654.42 ± 267.86 6,084.22 ± 648.83 9,323.07 ± 754.96 2,177.045 ± 128.14 965.96 ± 24.06 66.80 ± 4.91

Eriodictyol Liver 16.96 ± 1.61 30.10 ± 4.27 36.17 ± 5.19 13.66 ± 1.89 8.19 ± 0.65 3.16 ± 2.73 0.00
Spleen 0.00 11.15 ± 1.26 25.17 ± 2.83 39.09 ± 2.48 0.00 0.00 0.00
Lung 47.00 ± 3.08 20.90 ± 3.85 15.87 ± 2.04 7.50 ± 0.47 5.48 ± 0.81 0.00 0.00
Stomach 57.23 ± 5.34 64.35 ± 9.44 70.60 ± 10.74 146.73 ± 19.87 66.77 ± 8.91 11.51 ± 1.30 0.00
Uterus 8.60 ± 0.74 9.54 ± 0.88 35.62 ± 2.90 8.08 ± 1.13 0.00 0.00 0.00
Ovary 5.97 ± 0.80 8.92 ± 0.63 24.97 ± 2.10 8.80 ± 1.10 6.30 ± 0.98 0.00 0.00
Intestine 21.73 ± 2.65 83.46 ± 11.14 130.28 ± 19.34 43.59 ± 3.71 13.44 ± 1.34 8.58 ± 1.31 0.00

Naringenin Heart 3.23 ± 0.34 8.60 ± 0.87 10.44 ± 0.94 18.90 ± 1.48 37.96 ± 3.42 95.36 ± 10.72 14.82 ± 1.66
Liver 14.98 ± 1.42 26.78 ± 2.39 40.47 ± 1.03 121.58 ± 11.64 616.85 ± 60.73 413.12 ± 50.73 15.99 ± 1.67
Spleen 8.09 ± 1.07 12.22 ± 2.12 15.01 ± 2.10 83.01 ± 10.49 69.71 ± 6.26 111.57 ± 13.09 15.14 ± 8.78
Lung 7.67 ± 2.00 26.33 ± 7.58 37.52 ± 9.28 54.69 ± 5.73 61.63 ± 4.50 94.13 ± 9.13 10.88 ± 5.77
Kidney 2.91 ± 0.35 8.62 ± 0.78 54.76 ± 4.29 41.12 ± 3.67 47.99 ± 5.03 175.34 ± 12.62 5.08 ± 0.59
Brain 3.96 ± 0.40 9.95 ± 1.05 5.91 ± 0.78 13.22 ± 1.36 11.52 ± 1.53 18.79 ± 2.11 0.00
Stomach 136.19 ± 16.40 164.32 ± 14.87 255.32 ± 19.99 393.85 ± 35.16 323.57 ± 33.94 210.95 ± 15.19 0.00
Uterus 10.67 ± 1.07 17.14 ± 1.80 99.58 ± 13.09 47.72 ± 4.90 120.04 ± 15.89 100.46 ± 11.27 0.00
Ovary 6.55 ± 0.45 9.46 ± 0.55 19.22 ± 1.78 58.95 ± 4.08 67.62 ± 5.38 87.30 ± 8.30 0.00
Intestine 57.06 ± 4.18 84.62 ± 4.79 142.69 ± 17.30 391.10 ± 44.99 565.62 ± 45.04 499.71 ± 47.52 0.00

Kaempferol Liver 0.00 0.00 7.75 ± 1.12 37.65 ± 2.13 43.61 ± 5.29 10.18 ± 1.17 0.00
Spleen 0.00 13.30 ± 1.51 199.66 ± 23.11 25.68 ± 2.71 24.49 ± 2.99 16.70 ± 1.08 0.00
Lung 12.21 ± 1.28 22.19 ± 2.73 32.75 ± 4.10 15.20 ± 1.15 5.19 ± 0.81 3.52 ± 1.14 0.00
Kidney 0.66 ± 0.06 20.79 ± 2.41 38.34 ± 4.51 67.31 ± 5.19 29.74 ± 3.31 0.00 0.00
Stomach 7.46 ± 0.75 20.55 ± 2.16 24.88 ± 3.27 34.72 ± 3.56 17.44 ± 2.31 2.73 ± 0.31 0.00
Uterus 3.03 ± 0.27 6.23 ± 0.72 21.54 ± 2.53 15.86 ± 1.22 11.30 ± 1.26 5.64 ± 0.63 0.00
Intestine 25.24 ± 1.48 54.96 ± 5.09 159.55 ± 11.04 120.50 ± 9.60 98.37 ± 9.36 46.17 ± 3.34 0.00

Neoeriocitrin, luteolin-7-O-β-D-glucoside, astragalin, naringin, and naringenin are distributed in the heart, liver, spleen, lung, kidney, brain, stomach, uterus, ovary, and small intestine. Eriodictyol was not detected in the heart, kidney, and brain but was distributed in other tissues; kaempferol was not detected in the heart, brain, and ovary and was distributed to other tissues.

After oral administration of TFDR in rats, the highest tissue concentration of neoeriocitrin was detected in the intestine (8,133.84 ng/g), followed by the spleen (8,008.91 ng/g), the lung (7,837.09 ng/g), the stomach (7,324.59 ng/g), and the liver (3,247.80 ng/g) in 8-month-old rats. However, the highest tissue concentration of neoeriocitrin was detected in the intestine (6,236.26 ng/g), followed by the lung (6,223.83 ng/g), the spleen (5,970.17 ng/g), the stomach (5,552.27 ng/g), and the liver (2,431.18 ng/g) in 18-month-old rats. From the results, we found that the maximum concentration of neoeriocitrin was observed in the intestine, which may be mainly attributed to the oral mode of administration. The concentration of total neoeriocitrin in the lung was significantly higher than that in other tissues in rats, demonstrating that neoeriocitrin was mainly accumulated in the lung suggesting a potential role of this organ in the metabolism of neoeriocitrin. The total neoeriocitrin exhibited a litter lower concentration in the heart, liver, kidney, brain, uterus, and ovary, which indicate that blood flow and the organ did not play a key role in the distribution of neoeriocitrin. In addition, neoeriocitrin could be detected in the brain, which illustrated that could transfer across the blood-brain barrier, which may be related to the treatment of brain-related diseases, and further study is necessary.

Luteolin-7-O-β-D-glucoside and astragalin are mainly distributed into the digestive system of the rat's body after oral administration of TFDR. In the timescale, the peak concentration of luteolin-7-O-β-D-glucoside and astragalin appeared at different time points for the different tissues in 8-month-old and 18-month-old rats. The highest concentration was found in the stomach at 0.5 h in 8-month-old rats, while for 18-month-old rats, it was detected in the intestine at 2 h. For astragalin, the highest concentration was found in the stomach at 2 h in 8-month-old and 18-month-old rats. After 2 h, levels of luteolin-7-O-β-D-glucoside and astragalin in all tissues went down with the time. The distribution of luteolin-7-O-β-D-glucoside and astragalin in the brain showed that it had the ability to cross the blood-brain barrier after oral administration, which may be related to the treatment of brain-related diseases, and further research is still needed. It was showed that luteolin-7-O-β-D-glucoside and astragalin were mainly distributed in the stomach and intestine, which implied the stomach may be the major organ to absorb them.

Naringin, as the highest abundant flavonoids in TFDR, shows a wide distribution in all the tissues, and a small amount also crosses the blood-brain barrier. Compared with other tissues, it was less distributed in the heart and brain of rats. Tissue-to-plasma AUC ratio (T/P ratio) suggested that the maximum amount of drug was found in the intestine and liver; this finding was expected when the drug has given by oral administration and when it has major first-pass metabolism in the liver and intestine [17, 18]. However, it was more distributed in stomach, intestine, and ovary in old rats; this result indicated that it may regulate the autonomic nervous dysfunction of the cerebrospinal system through the hypothalamus-pituitary-ovary axis, thus playing an anti-AD role, but further research is needed [19].

The peak concentration of naringenin, the aglycone of naringin, was observed in the stomach at 2 h in 8-month-old and 18-month-old rats, followed by intestine at 4 h, and decreased gradually with time in tissues; this indicated that naringenin had strong selectivity to liver and kidney. Naringenin is slowly absorbed in liver and kidney tissues and has a long action time, which may be due to the metabolism of naringin into naringenin in vivo [20, 21]. It is speculated that this phenomenon may be related to the traditional Chinese medicine theory that there is a certain relationship between the liver and kidney meridian.

The peak concentration of eriodictyol was observed in the liver tissue; this phenomenon may be related to the traditional Chinese medicine theory that there is a certain relationship between the liver and kidney meridian. It could hardly be detected in the heart and brain.

Kaempferol is also widely and rapidly distributed into various tissues. There was more distribution in the spleen of rats at 1 h, indicating that kaempferol has a strong affinity with the spleen. There was more distribution in the kidney of rats at 2 h. The reason for the higher content of kidney tissue may be that the kidney is the main metabolic organ of the drug, and most of the drugs are excreted through the kidney. It could hardly be detected in the heart and brain [22].

According to the tissue distribution of seven compounds in the total Drynariae Rhizoma flavonoids in the young group and the old group, it was found that naringenin was rapidly absorbed in the stomach. However, naringin and neoeriocitrin were hydrolyzed into aglycons or absorbed in the belly of rats. The glycosides connected with one sugar at R3 (neoeriocitrin, eriodictyol, and luteolin-7-O-β-D-glucoside) are mainly distributed in the small intestine. Few tests in the kidney indicate that they may be transformed through the liver and discharged into the small intestine from the bile, converted into prototype drugs by corresponding hydrolases, and reabsorbed. It can be seen that the structure of the mother nucleus of flavonoids and the number and location of linked glycosyls will affect the tissue distribution. Clarifying the mechanism of these interactions is of great significance to increase the safety of the clinical medication and promote the development and clinical application of flavonoids.

This is the first study to examine the tissue distribution profile of multiple bioactive components after oral administration of TFDR. The results of the tissue distribution study showed that the seven analytes were of TFDR distributed mainly into the gastrointestinal tract, which provided the material basis for its pharmacological actions in clinical application.

4. Conclusions

In this study, a rapid and validated UPLC-MS/MS method for simultaneous determination of the seven analytes in rat tissue was successfully applied after oral administration of TFDR to rats. To the best of our knowledge, this is the first report of the UPLC-MS/MS method on the tissue distribution of the seven analytes in rats. The tissue distribution results achieved might be useful for further study of the bioactive mechanism of Drynariae Rhizoma. The validation procedure confirmed that the method was sensitive and selective and was suitable for the analysis of the seven analytes in biological samples. The present study could promote understanding the distribution of TFDR in vivo and provide the material basis for the dose regimen in the clinic.

Acknowledgments

This work was financially supported by the National Natural Science Foundation of China (81673621 and 81673581); Science and Technology Improvement Program of Harbin Normal University (14XYG-03); Scientific Research Fund of Heilongjiang University of Chinese Medicine (2015 xy04); Provincial Universities Technological Achievements Research and Cultivation Fund (TSTAU-C2018020); Youth Project of National Natural Science Foundation of China (82003975); and Scientific Research Project of Heilongjiang Provincial Health Committee (2020-301).

Abbreviations

UPLC-MS/MS:

Ultra performance liquid chromatography tandem mass spectrometry

TFDR:

Total flavonoids from Drynariae Rhizoma

MRM:

Multiple reactions monitoring

IS:

Internal standard

ESI+:

Positive ion mode of electrospray ionization

ACN:

Acetonitrile

MeOH:

Methanol

QC:

Quality control

LOD:

Limit of detection

LOQ:

Limit of quantitation

S/N:

Signal-to-noise ratio

RSD:

Relative standard deviations

RE:

Relative error.

Contributor Information

Fang Geng, Email: gengfang1980@163.com.

Ning Zhang, Email: zhangning0454@163.com.

Data Availability

No data were used to support this study.

Conflicts of Interest

The authors declare that there are no conflicts of interest with respect to this study.

References

  • 1.Mendez M. F. Early-onset Alzheimer disease and its variants. Continuum: Lifelong Learning in Neurology . 2019;25 doi: 10.1212/con.0000000000000687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Anand A., Patience A. A., Sharma N., Khurana N. The present and future of pharmacotherapy of Alzheimer’s disease: a comprehensive review. European Journal of Pharmacology . 2017;815:364–375. doi: 10.1016/j.ejphar.2017.09.043. [DOI] [PubMed] [Google Scholar]
  • 3.Liu P., Kong M., Liu S., Chen G., Wang P. Effect of reinforcing kidney-essence, removing phlegm, and promoting mental therapy on treating Alzheimer’s disease. Journal of Traditional Chinese Medicine . 2013;33(4):449–454. doi: 10.1016/s0254-6272(13)60147-8. [DOI] [PubMed] [Google Scholar]
  • 4.Liu M., Liu J., Hao L., Liu L., Zhou W. Research thoughts and methods on concise prescriptions of Chinese medicine for prevention and treatment of Alzheimer’s disease based on various kinds of animal models. World Science and Technology (Modernization of Traditional Chinese Medicine and Materia Medica) . 2012;14(2):1367–1376. [Google Scholar]
  • 5.Zhang Y. L., Zhou Z., Song W. S. Discussion on researches about theory of ‘kidney-Alzheimer’s disease-stem cells’. China Journal of Traditional Chinese Medicine & Pharmacy . 2017;32(1):60–63. [Google Scholar]
  • 6.Zhang S., Wei Y., Hao L. I. Central nervous system regeneration of patients with Alzheimer’s disease: based on the kidney-brain related theory. Journal of Traditional Chinese Medicine . 2018;59(2):120–123. [Google Scholar]
  • 7.Chen S., Yao X., Liang Y. Alzheimer’s disease treated with combined therapy based on nourishing marrow and reinforcing Qi. Journal of Traditional Chinese Medicine . 2015;35(3):255–259. doi: 10.1016/s0254-6272(15)30094-7. [DOI] [PubMed] [Google Scholar]
  • 8.Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China . Beijing, China: The Medicine Science and Technology Press of China; 2015. [Google Scholar]
  • 9.Cao H., Tuo L., Tuo Y., et al. Immune and metabolic regulation mechanism of dangguiliuhuang decoction against insulin resistance and hepatic steatosis. Frontiers in Pharmacology . 2017;8:p. 445. doi: 10.3389/fphar.2017.00445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Zhang Y., Jiang J., Shen H., Chai Y., Wei X., Xie Y. Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice. Drug Design, Development and Therapy . 2017;11:1881–1890. doi: 10.2147/dddt.s139804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Liu T., Hui C., Ji Y. Interaction of dendritic cells and T lymphocytes for the therapeutic effect of Dangguiliuhuang decoction to autoimmune diabetes. Scientific Reports . 2015;5(4) doi: 10.1038/srep13982.13982 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Song S.-h., Zhai Y.-k., Li C.-q., et al. Effects of total flavonoids from Drynariae Rhizoma prevent bone loss in vivo and in vitro. BoneKEy Reports . 2016;5:262–273. doi: 10.1016/j.bonr.2016.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wang W., Li H., Yu J., et al. Protective effects of Chinese herbal medicine Rhizoma drynariae in rats after traumatic brain injury and identification of active compound. Molecular Neurobiology . 2016;53(7):4809–4820. doi: 10.1007/s12035-015-9385-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zhang N., Hu Z., Zhang Z., et al. Protective role of naringenin against Aβ25-35-caused damage via ER and PI3K/Akt-mediated pathways. Cellular & Molecular Neurobiology . 2018;38(2):549–557. doi: 10.1007/s10571-017-0519-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Yang Z. Y., Kuboyama T., Kazuma K., Konno K., Tohda C. Active constituents from Drynaria fortunei rhizomes on the attenuation of Aβ25-35-induced axonal atrophy. Journal of Natural Products . 2015;78(9) doi: 10.1021/acs.jnatprod.5b00290. [DOI] [PubMed] [Google Scholar]
  • 16.Xu Z.-L., Xu M.-Y., Wang H.-T., et al. Pharmacokinetics of eight flavonoids in rats assayed by UPLC-MS/MS after oral administration of Drynariae rhizoma extract. Journal of Analytical Methods in Chemistry . 2018;2018:11. doi: 10.1155/2018/4789196.4789196 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Xie Y. M., Deng W. L., Hong Z. Study on drug-time process of osteopractic aurantiin in rhizoma drynariae. Traditional Chinese Drug Research & Clinical Pharmacology . 2005;16(5):350–352. [Google Scholar]
  • 18.Tsai T.-H. Determination of naringin in rat blood, brain, liver, and bile using microdialysis and its interaction with cyclosporin A, a P-glycoprotein modulator. Journal of Agricultural and Food Chemistry . 2002;50(23):6669–6674. doi: 10.1021/jf020603p. [DOI] [PubMed] [Google Scholar]
  • 19.Liu X., Chen W., Tu Y., et al. The abnormal functional connectivity between the hypothalamus and the temporal gyrus underlying depression in Alzheimer’s disease patients. Frontiers in Aging Neuroscience . 2018;10:p. 37. doi: 10.3389/fnagi.2018.00037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Yang C.-P., Liu M.-H., Zou W., Guan X.-L., Lai L., Su W.-W. Toxicokinetics of naringin and its metabolite naringenin after 180-day repeated oral administration in beagle dogs assayed by a rapid resolution liquid chromatography/tandem mass spectrometric method. Journal of Asian Natural Products Research . 2012;14(1):68–75. doi: 10.1080/10286020.2011.632369. [DOI] [PubMed] [Google Scholar]
  • 21.Ma Y., Lin B. Q., Li W. Z. Absorption kinetics of naringenin in rat intestines. Chinese Traditional Patent Medicine . 2012;34(8):1487–1491. [Google Scholar]
  • 22.Zhou N., Qin Y., Zhou Z. Effect of grycyrrhetinic acid on the tissue distributions of kaempferol in rats. Pharmacology & Clinics of Chinese Materia Medica . 2013;6:35–38. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

No data were used to support this study.


Articles from Journal of Analytical Methods in Chemistry are provided here courtesy of Wiley

RESOURCES